Anti-angiogenic drugs: From bench to clinical trials

Medicinal Research Reviews

Volumn 26, Issue 4, 2006, Pages 483-530

  Quesada, Ana R ^a   Muñoz Chápuli, Ramón ^a   Medina, Miguel A ^a  

^a UNIVERSITY OF MÁLAGA   (Spain)

Author keywords

Angiogenesis; Cancer; Clinical trials; Inhibitors; Macular degeneration

Indexed keywords

2 (8 HYDROXY 6 METHOXY 1 OXO 1H 2 BENZOPYRAN 3 YL)PROPIONIC ACID; 2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; 3 [4 METHYL 2 (2 OXO 3 INDOLINYLMETHYLIDENYL) 3 PYRROLYL]PROPIONIC ACID; 4 DEDIMETHYLAMINOSANCYCLINE; 4,4' [CARBONYLBIS[IMINO 1H PYRROLE 4,2 DIYLCARBONYLIMINO(1 METHYL 1H PYRROLE 4,2 DIYL)CARBONYLIMINO]]BIS(1,7 NAPHTHALENESULFONIC ACID); AE 941; AGM 1479; ALPHA INTERFERON; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BASIC FIBROBLAST GROWTH FACTOR; BATIMASTAT; BB 2626; BEVACIZUMAB; CARBOPLATIN; CETUXIMAB; CGS 27023A; ERLOTINIB; EVEROLIMUS; FUMAGILLOL CHLOROACETYLCARBAMATE; MARIMASTAT; MONOCLONAL ANTIBODY LM 609; MSI 1256F; N (4 BROMO 2 FLUOROPHENYL) 6 METHOXY 7 [2 (1H 1,2,3 TRIAZOL 1 YL)ETHOXY] 4 QUINAZOLINAMINE; PACLITAXEL; PD 166866; PENTOSAN POLYSULFATE; PRINOMASTAT; REBIMASTAT; SEMAXANIB; SOLIMASTAT; SORAFENIB; SQUALAMINE; SU 4984; SUNITINIB; SURAMIN; TANOMASTAT; TECOGALAN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANDETANIB; VASCULOTROPIN; VASCULOTROPIN RECEPTOR; VATALANIB;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTHRITIS; ATHEROSCLEROSIS; BREAST CARCINOMA; CAPILLARY; CELL DIFFERENTIATION; CELL MIGRATION; CELL PROLIFERATION; CHILL; CLINICAL TRIAL; COLON ADENOCARCINOMA; COLORECTAL CANCER; DIABETIC RETINOPATHY; EPISTAXIS; FEVER; GASTROINTESTINAL STROMAL TUMOR; GLIOBLASTOMA; HEAD AND NECK CANCER; HEADACHE; HEMANGIOMA; HEPATOBLASTOMA; HUMAN; HYPERTENSION; KAPOSI SARCOMA; KIDNEY CARCINOMA; LEIOMYOSARCOMA; LEUKEMIA; LIVER CANCER; LUNG CANCER; LYMPHOMA; MELANOMA; MESOTHELIOMA; METASTASIS; MYELOMA; NEPHROBLASTOMA; NEUROBLASTOMA; NEUROTOXICITY; NONHUMAN; OVARY CARCINOMA; PANCREAS CANCER; PROSTATE CARCINOMA; PSORIASIS; RASH; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; RHABDOMYOSARCOMA; SARCOMA; SOLID TUMOR; TUMOR GROWTH; VASCULAR ENDOTHELIUM;

ANGIOGENESIS INHIBITORS; ANIMALS; CLINICAL TRIALS; CLINICAL TRIALS AS TOPIC; HUMANS; MACULAR DEGENERATION; MODELS, BIOLOGICAL; MODELS, CHEMICAL; MODELS, MOLECULAR; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; SIGNAL TRANSDUCTION;

EID: 33745305095     PISSN: 01986325     EISSN: None     Source Type: Journal    
DOI: 10.1002/med.20059     Document Type: Review

References (424)

1. Gasparini G. The rationale and future potential of angiogenesis inhibitors in neoplasia. Drugs 1999;58: 17-38.
2. Kerbel RS. A cancer therapy resistant to resistance. Nature 1997;390:335-336.
3. Brekken RA, Overholser JP, Stastny VA, Waltenberger J, Minna JD, Thorpe PE. Selective inhibition of vascular endothelial growth factor (VEGF) receptor 2 (KDR/Flk-1) activity by a monoclonal anti-VEGF antibody blocks tumor growth in mice. Cancer Res 2000;60:5117-5124.
4. Gerber HP, Ferrara N. Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res 2005;65:671-680.
5. Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS, Ferrara N. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993;362:841-844.
6. Fernando NH, Hurwitz HI. Targeted therapy of colorectal cancer: Clinical experience with bevacizumab. Oncologist 2004;9(Suppl 1):11-18.
7. Burke PA, DeNardo SJ. Antiangiogenic agents and their promising potential in combined therapy. Crit Rev Oncol Hematol 2001;39:155-171.
8. Kabbinavar F, Hurwitz HI, Fehrenbacher L, Meropol NJ, Novotny WF, Lieberman G, Griffing S, Bergsland E. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003;21:60-65.
9. Hurwitz H, Fehrenbacher L, Cartwright T, Hainsworth J, Hein W, Berlin J, Griffing S, Novotny W, Holmgren E, Kabbinavar F. Bevacizumab (a monoclonal antibody to vascular endothelial growth factor) prolongs survival in first-line colorectal cancer (CRC): Results of a phase III trial of bevacizumab in combination with bolus IFL (irinotecan, 5-FU-LV) as a first-line therapy in subjects with metastatic CRC. Proc Am Soc Clin Oncol; 22: Abstract 3645.
10. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-2342.
11. Mitchell EP, Alberts SR, Schwartz MA, Giantonio BJ, Catalano PJ, Meropol NJ, O'Dwyer PJ, Benson AB. High-dose bevacizumab in combination with FOLFOX4 improves survival in patients with previously treated advanced colorectal cancer: Results from the Eastern Cooperative Oncology Group (ECOG) study E3200. Gastrointestinal Cancers Symposium 2005; Abstract No: 169a.
12. Giantonio BJ, Catalano PJ, Meropol NJ, O'Dwyer PJ, Mitchell EP, Alberts SR, Schwartz MA, Benson AB. High-dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: Results from the Eastern Cooperative Oncology Group (ECOG) study E3200. J Clin Oncol (ASCO Meeting Abstracts) 2005;23:2.
13. Rini BI. VEGF-targeted therapy in metastatic renal cell carcinoma. Oncologist 2005;10:191-197.
14. Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL, Steinberg SM, Chen HX, Rosenberg SA. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003;349:427-434.
15. Hainsworth J, Sosman J, Spigel D, Schwert RC, Carrell DL, Hubbard F, Greco FA. Phase II trial of bevacizumab and erlotinib in patients with metastatic renal carcinoma (RCC). J Clin Oncol (Meeting Abstracts) 2004;22:4502.
16. Spigel DR, Hainsworth JD, Sosman JA, Raefsky EL, Meluch AA, Edwards D, Horowitz P, Thomas K, Yost K, Stagg MP, Greco FA. Bevacizumab and erlotinib in the treatment of patients with metastatic renal carcinoma (RCC): Update of a phase II multicenter trial. J Clin Oncol (Meeting Abstracts) 2005;23:4540.
17. Rini BI, Halabi S, Taylor J, Small EJ, Schilsky RL; Cancer and Leukemia Group B. 90206: A randomized phase III trial of interferon-alpha or interferon-alpha plus anti-vascular endothelial growth factor antibody (bevacizumab) in metastatic renal cell carcinoma. Clin Cancer Res 2004;10:2584-2586.
18. Miller KD, Chap LI, Holmes FA, Cobleigh MA, Marcom PK, Fehrenbacher L, Dickler M, Overmoyer BA, Reimann JD, Sing AP, Langmuir V, Rugo HS. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005;23:792-799.
19. Miller KD, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, Shenker TN, Davidson NE. E2100: A randomized phase III trial of paclitaxel plus bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer. Proc Am Soc Clin Oncol 2005. Late-breaking session.
20. Johnson DH, Fehrenbacher L, Novotny WF, Herbst RS, Nemunaitis JJ, Jablons DM, Langer CJ, De Vore RF 3rd, Gaudreault J, Damico LA, Holmgren E, Kabbinavar F. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004;22:2184-2191.
21. Herbst RS, Johnson DH, Mininberg E, Carbone DP, Henderson T, Kim ES, Blumenschein G, Jr., Lee JJ, Liu DD, Truong MT, Hong WK, Tran H, Tsao A, Xie D, Ramies DA, Mass R, Seshagiri S, Eberhard DA, Kelley SK, Sandler A. Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer. J Clin Oncol 2005;23:2544-2555.
22. Sandler AB, Gray R, Brahmer J, Dowlati A, Sehiller JH, Perry MC, Johnson DH. Randomized phase II/III trial of paelitaxel (P) plus carboplatin (C) with or without bevacizumab (NSC #704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): An Eastern Cooperative Oncology Group (ECOG) Trial-E4599. J Clin Oncol (Meeting Abstracts) 2005;23:LBA4.
23. Barleon B, Reusch P, Totzke F, Herzog C, Keck C, Martiny-Baron G, Marme D. Soluble VEGFR-1 secreted by endothelial cells and monocytes is present in human serum and plasma from healthy donors. Angiogenesis 2001;4:143-154.
24. Lin P, Polverini P, Dewhirst M, Shan S, Rao PS, Peters K. Inhibition of tumor angiogenesis using a soluble receptor establishes a role for Tie2 in pathologic vascular growth. J Clin Invest 1997;100:2072-2078.
25. Lin P, Sankar S, Shan S, Dewhirst MW, Polverini PJ, Quinn TQ, Peters KG. Inhibition of tumor growth by targeting tumor endothelium using a soluble vascular endothelial growth factor receptor. Cell Growth Differ 1998;9:49-58.
26. Hoshida T, Sunamura M, Duda DG, Egawa S, Miyazaki S, Shineha R, Hamada H, Ohtani H, Satomi S, Matsuno S. Gene therapy for pancreatic cancer using an adenovirus vector encoding soluble fit-1 vascular endothelial growth factor receptor. Pancreas 2002;25:111-121.
27. Takayama K, Ueno H, Nakanishi Y, Sakamoto T, Inoue K, Shimizu K, Oohashi H, Hara N. Suppression of tumor angiogenesis and growth by gene transfer of a soluble form of vascular endothelial growth factor receptor into a remote organ. Cancer Res 2000;60:2169-2177.
28. Ogawa T, Takayama K, Takakura N, Kitano S, Ueno H. Anti-tumor angiogenesis therapy using soluble receptors: Enhanced inhibition of tumor growth when soluble fibroblast growth factor receptor-1 is used with soluble vascular endothelial growth factor receptor. Cancer Gene Ther 2002;9:633-640.
29. Holash J, Davis S, Papadopoulos N, Croll SD, Ho L, Russell M, Boland P, Leidich R, Hylton D, Burova E, Ioffe E, Huang T, Radziejewski C, Bailey K, Fandl JP, Daly T, Wiegand SJ, Yancopoulos GD, Rudge JS. VEGF-Trap: A VEGF blocker with potent antitumor effects. Proc Natl Acad Sci USA 2002;99:11393-11398.
30. Kim ES, Serur A, Huang J, Manley CA, McCrudden KW, Frischer JS, Soffer SZ, Ring L, New T, Zabisky S, Rudge JS, Holash J, Yancopoulos GD, Kandel JJ, Yamashiro DJ. Potent VEGF blockade causes regression of coopted vessels in a model of neuroblastoma. Proc Natl Acad Sci USA 2002;99:11399-11404.
31. Byrne AT, Ross L, Holash J, Nakanishi M, Hu L, Hofmann JI, Yancopoulos GD, Jaffe RB. Vascular endothelial growth factor-trap decreases tumor burden, inhibits ascites, and causes dramatic vascular remodeling in an ovarian cancer model. Clin Cancer Res 2003;9:5721-5728.
32. Huang J, Frischer JS, Serur A, Kadenhe A, Yokoi A, McCrudden KW, New T, O'Toole K, Zabski S, Rudge JS, Holash J, Yancopoulos GD, Yamashiro DJ, Kandel JJ. Regression of established tumors and metastases by potent vascular endothelial growth factor blockade. Proc Natl Acad Sci USA 2003;100:7785-7790.
33. Saishin Y, Saishin Y, Takahashi K, Lima e Silva R, Hylton D, Rudge JS, Wiegand SJ, Campochiaro PA. VEGF-TRAP(R1R2) suppresses choroidal neovascularization and VEGF-induced breakdown of the blood-retinal barrier. J Cell Physiol 2003;195:241-248.
34. Dupont J, Rothenberg ML, Spriggs DR, Cedarbaum JM, Furfine ES, Cohen DP, Dancy I, Lee HS, Cooper W, Lockhart AC. Safety and pharmacokinetics of intravenous VEGF Trap in a phase I clinical trial of patients with advanced solid tumors. J Clin Oncol (Meeting Abstracts) 2005;23:3029.
35. Liekens S, De Clercq E, Neyts J. Angiogenesis: regulators and clinical applications. Biochem Pharmacol 2001;61:253-270.
36. Von Marschall Z, Scholz A, Cramer T, Schafer G, Schirner M, Oberg K, Wiedenmann B, Hocker M, Rosewicz S. Effects of interferon alpha on vascular endothelial growth factor gene transcription and tumor angiogenesis. J Natl Cancer Inst 2003;95:437-448.
37. Dubois J, Hershon L, Carmant L, Belanger S, Leclerc JM, David M. Toxicity profile of interferon alfa-2b in children: A prospective evaluation. J Pediatr 1999;135:782-785.
38. Chang E, Boyd A, Nelson CC, Crowley D, Law T, Keough KM, Folkman J, Ezekowitz RA, Castle VP. Successful treatment of infantile hemangiomas with interferon-alpha-2b. J Pediatr Hematol Oncol 1997;19:237-244.
39. Tamayo L, Ortiz DM, Orozco-Covarrubias L, Duran-McKinster C, Mora MA, Avila E, Teixeira F, Ruiz-Maldonado R. Therapeutic efficacy of interferon alfa-2b in infants with life-threatening giant hemangiomas. Arch Dermatol 1997;133:1567-1571.
40. Kirkwood JM, Ibrahim JG, Sosman JA, Sondak VK, Agarwala SS, Ernstoff MS, Rao U. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: Results of intergroup trial E1694/S9512/C509801. J Clin Oncol 2001;19:2370-2380.
41. Kilbridge KL, Cole BF, Kirkwood JM, Haluska FG, Atkins MA, Ruckdeschel JC, Sock DE, Nease RF, Weeks JC. Quality-of-life-Adjusted survival analysis of high-dose adjuvant interferon alfa-2b for high-risk melanoma patients using intergroup clinical trial data. J Clin Oncol 2002;20:1311-1318.
42. Kirkwood JM, Bender C, Agarwala S, Tarhini A, Shipe-Spotloe J, Smelko B, Donnelly S, Stover L. Mechanisms and management of toxicities associated with high-dose interferon alfa-2b therapy. J Clin Oncol 2002;20:3703-3718.
43. Kiss C, Kiss M, Szegedi I, Arvai K, Toth J, Olah E. Interferon-alpha therapy in children with malignant diseases: Clinical experience in twenty-four patients treated in a single pediatric oncology unit. Med Pediatr Oncol 2002;39:115-119.
44. Lens MB, Dawes M. Interferon alfa therapy for malignant melanoma: A systematic review of randomized controlled trials. J Clin Oncol 2002;20:1818-1825.
45. Hauschild A, Weichenthal M, Balda BR, Becker JC, Wolff HH, Tilgen W, Schulte KW, Ring J, Schadendorf D, Lischner S, Burg G, Dummer R. Prospective randomized trial of interferon alfa-2b and interleukin-2 as adjuvant treatment for resected intermediate- and high-risk primary melanoma without clinically detectable node metastasis. J Clin Oncol 2003;21:2883-2888.
46. Hancock BW, Wheatley K, Harris S, Ives N, Harrison G, Horsman JM, Middleton MR, Thatcher N, Lorigan PC, Marsden JR, Burrows L, Gore M. Adjuvant interferon in high-risk melanoma: The AIM HIGH Study-United Kingdom Coordinating Committee on Cancer Research Randomized Study of Adjuvant Low-Dose Extended-Duration Interferon Alfa-2a in High-Risk Resected Malignant Melanoma. J Clin Oncol 2004;22:53-61.
47. Kirkwood JM, Manola J, Ibrahim J, Sondak V, Ernstoff MS, Rao U. A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma. Clin Cancer Res 2004;10:1670-1677.
48. Moschos SJ, Kirkwood JM, Konstantinopoulos PA. Present status and future prospects for adjuvant therapy of melanoma: Time to build upon the foundation of high-dose interferon alfa-2b. J Clin Oncol 2004;22:11-14.
49. Sunkara U, Walczak JR, Summerson L, Rogers T, Eisenberger M, Denmeade S, Pili R, Huff CA, Sinibaldi V, Carducci MA. A phase II trial of temozolomide and IFN-alpha in patients with advanced renal cell carcinoma. J Interferon Cytokine Res 2004;24:37-41.
50. Schuchter LM. Adjuvant interferon therapy for melanoma: High-dose, low-dose, no dose, which dose?. J Clin Oncol. 2004;22:7-10.
51. Hosang M. Suramin binds to platelet-derived growth factor and inhibits its biological activity. J Cell Biochem 1985;29:265-273.
52. Danesi R, Del BS, Soldani P, Campagni A, La RR, Myers CE, Paparelli A, Del TM. Suramin inhibits bFGF-induced endothelial cell proliferation and angio-genesis in the chick chorioallantoic membrane. Br J Cancer 1993;68:932-938.
53. Middaugh CR, Mach H, Burke CJ, Volkin DB, Dabora JM, Tsai PK, Bruner MW, Ryan JA, Marfia KE. Nature of the interaction of growth factors with suramin. Biochemistry 1992;31:9016-9024.
54. Waltenberger J, Mayr U, Frank H, Hombach V. Suramin is a potent inhibitor of vascular endothelial growth factor. A contribution to the molecular basis of its antiangiogenic action. J Mol Cell Cardiol 1996;28:1523-1529.
55. Takano S, Gately S, Neville ME, Herblin WF, Gross JL, Engelhard H, Perricone M, Eidsvoog K, Brem S. Suramin, an anticancer and angiosuppressive agent, inhibits endothelial cell binding of basic fibroblast growth factor, migration, proliferation, and induction of urokinase-type plasminogen activator. Cancer Res 1994;54:2654-2660.
56. Bocci G, Danesi R, Benelli U, Innocenti F, Di Paolo A, Fogli S, Del Tacca M. Inhibitory effect of suramin in rat models of angiogenesis in vitro and in vivo. Cancer Chemother Pharmacol 1999;43:205-212,.
57. Pesenti E, Sola F, Mongelli N, Grandi M, Spreatico F. Suramin prevents neovascularisation and tumour growth through blocking of basic fibroblast growth factor activity. Br J Cancer 1992;66:367-372.
58. Kaur M, Reed E, Sartor O, Dahut W, Figg WD. Suramin's development: What did we learn? Invest New Drugs 2002;20:209-219.
59. Miglietta L, Canobbio L, Granetto C, Vannozzi MO, Esposito M, Boccardo F. Suramin/epidoxorubicin association in hormone-refractory prostate cancer: Preliminary results of a pilot phase II study. J Cancer Res Clin Oncol 1997;123:407-410.
60. Mirza MR, Jakobsen E, Pfeiffer P, Lindebjerg-Clasen B, Bergh J, Rose C. Suramin in non-small cell lung cancer and advanced breast cancer. Two parallel phase II studies. Acta Oncol 1997;36:171-174.
61. Kaur M, Reed E, Sartor O, Dahut W, Figg WD. Suramin's development: What did we learn? Invest New Drugs 2002;20:209-219.
62. Vogelzang NJ, Karrison T, Stadler WM, Garcia J, Cohn H, Kugler J, Troeger T, Giannone L, Arrieta R, Ratain MJ, Vokes EE. A Phase II trial of suramin monthly ×3 for hormone-refractory prostate carcinoma. Cancer 2004;100:65-71.
63. Braddock PS, Hu DE, Fan TP, Stratford IJ, Harris AL, Bicknell R. A structure-activity analysis of antagonism of the growth factor and angiogenic activity of basic fibroblast growth factor by suramin and related polyanions. Br J Cancer 1994;69:890-898.
64. Ciomei M, Pastori W, Mariani M, Sola F, Grandi M, Mongelli N, La Rocca RV, Stein CA, Danesi R, Cooper MR, Uhrich M, Myers CE. New sulfonated distamycin A derivatives with bFGF complexing activity. Biochem Pharmacol 1994;47:295-302.
65. Meyers MO, Gagliardi AR, Flattmann GJ, Su JL, Wang YZ, Woltering EA. Suramin analogs inhibit human angiogenesis in vitro. J Surg Res 2000;91:130-134.
66. Finch PW, Yee LK, Chu MY, Chen TM, Lipsky MH, Maciag T, Friedman S, Epstein MH, Calabresi P. Inhibition of growth factor mitogenicity and growth of tumor cell xenografts by a sulfonated distamycin A derivative. Pharmacology 1997;55:269-278.
67. Schneider GP, Salcedo R, Dong HF, Kleinman HK, Oppenheim JJ, Howard OM. Suradista NSC 651016 inhibits the angiogenic activity of CXCL12-stromal cell-derived factor 1alpha. Clin Cancer Res 2002;8:3955-3960.
68. Groen HJ, de Vries EG, Wynendaele W, van der Graaf WT, Fokkema E, Lechuga MJ, Poggesi I, Dirix LY, van Oosterom AT. PNU-145156E, a novel angiogenesis inhibitor, in patients with solid tumors: A phase I and pharmacokinetic study. Clin Cancer Res 2001;7:3928-3933.
69. Nguyen NM, Lehr JE, Pienta KJ. Pentosan inhibits angiogenesis in vitro and suppresses prostate tumor growth in vivo. Anticancer Res 1993;13:2143-2147.
70. Lush RM, Figg WD, Pluda JM, Bitton R, Headlee D, Kohler D, Reed E, Sartor O, Cooper MR. A phase I study of pentosan polysulfate sodium in patients with advanced malignancies. Ann Oncol 1996;7:939-944.
71. Marshall JL, Wellstein A, Rae J, DeLap RJ, Phipps K, Hanfelt J, Yunmbam MK, Sun JX, Duchin KL, Hawkins MJ. Phase I trial of orally administered pentosan polysulfate in patients with advanced cancer. Clin Cancer Res 1997;3:2347-2354.
72. Schwartsmann G, Sprinz E, Kalakun L, Yamagushi N, Sander E, Grivicich I, Koya R, Mans DR. Phase II study of pentosan polysulfate (PPS) in patients with AIDS-related Kaposi's sarcoma. Tumori 1996;82:360-363.
73. Teichman JMH. The role of pentosan polysulfate in treatment approaches for interstitial cystitis. Rev Urol 2002;4:S21-S27.
74. Ghosh P, Smith M. Osteoarthritis, genetic and molecular mechanisms. Biogerontology 2002;3:85-88.
75. Arora N, Masood R, Zheng T, Cai J, Smith DL, Gill PS. Vascular endothelial growth factor chimeric toxin is highly active against endothelial cells. Cancer Res 1999;59:183-188.
76. Veenendaal LM, Jin H, Ran S, Cheung L, Navone N, Marks JW, Waltenberger J, Thorpe P, Rosenblum MG. In vitro and in vivo studies of a VEGF121/rGelonin chimeric fusion toxin targeting the neovasculature of solid tumors Proc Natl Acad Sci USA 2002;99:7866-7871.
77. Frankel AE. Increased Sophistication of Immunotoxins. Clin Cancer Res 2002;8:942-944.
78. Zhu Z, Witte L. Inhibition of tumor growth and metastasis by targeting tumor associated angiogenesis with antagonists to the receptors of vascular endoithelial growth factor. Invest New Drugs 1999;17:195-212.
79. Usman N, Blatt LM. Nuclease-resistant synthetic ribozymes: Developing a new class of therapeutics. J Clin Invest 2000;106:1197-1202.
80. Parry TJ, Cushman C, Gallegos AM, Agrawal AB, Richardson M, Andrews LE, Maloney L, Mokler VR, Wincott FE, Pavco PA. Bioactivity of anti-angiogenic ribozymes targeting Flt-1 and KDR mRNA. Nucleic Acids Res 1999;27:2569-2577.
81. Parry TJ, Pavco PA, Sandberg JA. Ribozyme pharmacokinetic screening for predicting pharmacodynamic dosing regimens. In: Rossi J, Couture L, editors, Intracellular ribozyme applications: Principles and protocols. Wymondham, UK: Horizon Scientific Press. 1999.
82. Pavco PA, Bouhana KS, Gallegos AM, Agrawal A, Blanchard KS, Grimm SL, Jensen KL, Andrews LE, Wincott FE, Pilot PA, Tressler RJ, Cushman C, Reynolds MA, Parry TJ. Antitumor and antimetastatic activity of ribozymes targeting the mRNA of vascular growth factor receptors. Clinical Cancer Res 2000;6:2094-2103.
83. Sandberg JA, Sproul CD, Blanchard KS, Bellon L, Sweedler D, Powell JA, Caputo FA, Kornbrust DJ, Parker VP, Parry TJ, Blatt LM. Acute toxicology and pharmacokinetic assessment of a ribozyme (ANGIOZYME) targeting vascular endothelial growth factor receptor mRNA in the cynomolgus monkey. Antisense Nucleic Acid Drug Dev 2000;10:153-162.
84. Sandberg JA, Bouhana KS, Gallegos AM, Agrawal AB, Grimm SL, Wincott FE, Reynolds MA, Pavco PA, Parry TJ. Pharmacokinetics of an antiangiogenic ribozyme (ANGIOZYME) in the mouse. Antisense Nucleic Acid Drug Dev 1999;9:271-277.
85. Sandberg JA, Parker VP, Blanchard KS, Sweedler D, Powell JA, Kachensky A, Bellon L, Usman N, Rossing T, Borden E, Blatt LM. Pharmacokinetics and tolerability of an antiangiogenic ribozyme (ANGIOZYME) in healthy volunteers. J Clin Pharmacol 2000;40:1462-1469.
86. Weng DE, Usaman N. Angiozyme: A novel angiogenesis inhibitor. Curr Oncol Rep 2001;3:141-146.
87. Venook A, Hurwitz H, Cunningham C, Burris H, Aitchison R, Radka S, Pavco P, Capra W, Wolin M, Usman N. Relationship of clinical outcome in metastatic colorectal carcinoma to levels of soluble VEGFR-1: Results of a Phase II trial of ANGIOZYME, a ribozyme targeting the pre-mRNA of VEGFR-1, in combination with chemotherapy. Proc Am Soc Clin Oncol 2003;22:256, Abstract 1025.
88. Fairbrother WJ, Christinger HW, Cochran AG, Fuh G, Keenan CJ, Quan C, Shriver SK, Tom JY, Wells JA, Cunningham BC. Novel peptides selected to bind vascular endothelial growth factor target the receptor-binding site. Biochemistry 1998;37:17754-17764.
89. Hagedorn M, Bikfalvi A. Target molecules for anti-angiogenic therapy: From basic research to clinical trials. Crit Rev Oncol Hematol 2000;34:89-110.
90. Prewett M, Huber J, Li Y, Santiago A, O'Connor W, King K, Overholser J, Hooper A, Pytowski B, Witte L, Bohlen P, Hicklin DJ. Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors. Cancer Res 1999;59:5209-5218.
91. Kunkel P, Ulbricht U, Bohlen P, Brockmann MA, Fillbrandt R, Stavrou D, Westphal M, Lamszus K. Inhibition of glioma angiogenesis and growth in vivo by systemic treatment with a monoclonal antibody against vascular endothelial growth factor receptor-2. Cancer Res 2001;61:6624-6628.
92. Hicklin DJ, Witte L, Zhu Z, Liao F, Wu Y, Li Y, Bohlen P. Monoclonal antibody strategies to block angiogenesis. Drug Disc Today 2001;6:517-528.
93. Zhu Z, Rockwell P, Lu D, Kotanides H, Pytowski B, Hicklin DJ, Bohlen P, Witte L. Inhibition of vascular endothelial growth factor-induced receptor activation with anti-kinase insert domain-containing receptor single-chain antibodies from a phage display library. Cancer Res 1998;58:3209-3214.
94. Posey JA, Ng TC, Yang B, Khazaeli MB, Carpenter MD, Fox F, Needle M, Waksal H, LoBuglio AF. A phase I study of anti-kinase insert domain-containing receptor antibody, IMC-1C11, in patients with liver metastases from colorectal carcinoma. Clin Cancer Res 2003;9:1323-1332.
95. Lu D, Shen J, Vil MD, Zhang H, Jimenez X, Bohlen P, Witte L, Zhu Z. Tailoring in vitro selection for a picomolar affinity human antibody directed against vascular endothelial growth factor receptor 2 for enhanced neutralizing activity. J Biol Chem 2003;278:43496-43507.
96. Zhu Z, Hattori K, Zhang H, Jimenez X, Ludwig DL, Dias S, Kussie P, Koo H, Kim HJ, Lu D, Liu M, Tejada R, Friedrich M, Bohlen P, Witte L, Rafii S. Inhibition of human leukemia in an animal model with human antibodies directed against vascular endothelial growth factor receptor 2. Correlation between antibody affinity and biological activity. Leukemia 2003;17:604-611.
97. Zhu Z, Bohlen P, Witte L. Clinical development of angiogenesis inhibitors to vascular endothelial growth factor and its receptors as cancer therapeutics. Current Cancer Drug Targets 2002;2:135-156.
98. Jimenez X, Lu D, Brennan L, Persaud K, Liu M, Miao H, Witte L, Zhu Z. A recombinant, fully human, bispecific antibody neutralizes the biological activities mediated by both vascular endothelial growth factor receptors 2 and 3. Mol Cancer Ther 2005;4:427-434.
99. Fong TA, Shawver LK, Sun L, Tang C, App H, Powell TJ, Kim YH, Schreck R, Wang X, Risau W, Ullrich A, Hirth KP, McMahon G. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res 1999;59:99-106.
100. Shaheen RM, Davis DW, Liu W, Zebrowski BK, Wilson MR, Bucana CD, McConkey DJ, McMahon G, Ellis LM. Antiangiogenic therapy targeting the tyrosine kinase receptor for vascular endothelial growth factor receptor inhibits the growth of colon cancer liver metastasis and induces tumor and endothelial cell apoptosis. Cancer Res 1999;59:5412-5416.
101. Angelov L, Salhia B, Roncari L, McMahon G, Guha A. Inhibition of angiogenesis by blocking activation of the vascular endothelial growth factor receptor 2 leads to decreased growth of neurogenic sarcomas. Cancer Res 1999;59:5536-5541.
102. Schuuring J, Bussink J, Bernsen HJ, Peeters W, van Der Kogel AJ. Irradiation combined with SU5416: microvascular changes and growth delay in a human xenograft glioblastoma tumor line. Int J Radiat Oncol Biol Phys 2005;61:529-534.
103. Mendel DB, Schreck RE, West DC, Li G, Strawn LM, Tanciongco SS, Vasile S, Shawver LK, Cherrington JM. The angiogenesis inhibitor SU5416 has long-lasting effects on vascular endothelial growth factor receptor phosphorylation and function. Clin Cancer Res 2000;6:4848-4858.
104. Mendel DB, Laird AD, Smolich BD, Blake RA, Liang C, Hannah AL, Shaheen RM, Ellis LM, Weitman S, Shawver LK, Cherrington JM. Development of SU5416, a selective small molecule inhibitor of VEGF receptor tyrosine kinase activity, as an anti-angiogenesis agent. Anticancer Drug Des 2000;15: 29-41.
105. Via LE, Gore-Langton RE, Pluda JM. Clinical trials referral resource. Current clinical trials administering the antiangiogenesis agent SU5416. Oncology (Williston Park) 2000; 14:1312, 1315-1316, 1321-1323.
106. Eng C, Kindler HL, Stadler WM, Karczmar G, Heimann R, Wade JL, Nattam S, Agamah E, Vokes EE. SU5416 in advanced colorectal cancer (CRC): A University of Chicago Phase II Consortium Study. Proc Am Soc Clin Oncol 2001;20:116b.
107. Fiedler WM, Tinnefeld H, Mende T, Gehling U, Vohwinkel G, Kelsey S, Scigalla P, Hossfeld DK. A phase II study with SU5416 in patients with C-Kit positive AML. Proc Am Soc Clin Oncol 2001;20:288a.
108. Gajewski TF, Flickinger S, Heimann R, Karczmar G, Rini B, Dragovich T, Stadler WM. Phase II study of the anti-angiogenic Flk-1 tyrosine kinase inhibitor SU5416 in melanoma: Initial results. Proc Am Soc Clin Oncol 2001;20:360a.
109. Kindler HL, Vogelzang NJ, Chien K, Stadler W, Karczmar G, Heimann R, Vokes EE. SU5416 in malignant mesothelioma: A University of Chicago phase II consortium study. Proc Am Soc Clin Oncol 2001;20:341a.
110. Salzberg M, Pless M, Rochlitz C, Herrmann R, Cropp G, Hannah A, Scigalla P. A phase I and pharmacokinetic study of single oral administration of SU5416 in patients with advanced solid tumors. Proc Am Soc Clin Oncol 2001;20:98a.
111. Richard S, Croisille L, Yvart J, Casadeval N, Eschwège P, Aghakhani N, David P, Gaudric A, Scigalla P, Hermine O. Paradoxical secondary polycythemia in von Hippel-Lindau patients treated with anti-vascular endothelial growth factor receptor therapy. Blood 2002;99:3851-3853.
112. Giles FJ, Stopeck AT, Silverman LR, Lancet JE, Cooper MA, Hannah AL, Cherrington JM, O'Farrell AM, Yuen HA, Louie SG, Hong W, Cortes JE, Verstovsek S, Albitar M, O'Brien SM, Kantarjian HM, Karp JE. SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes. Blood 2003;102:795-801.
113. Kuenen BC, Levi M, Meijer JCM, Kakkar AK, van Hinsbergh VWM, Costéense PJ, Pinedo HM, Hoekman K. Analysis of coagulation cascade and endotelial cell activation during inhibition of vascular endotelial growth factor/vascular endothelial growth factor receptor pathway in cancer patients. Arterioscler Thromb Vase Biol 2002;22:1500-1505.
114. Heymach JV, Desai J, Manola J, Davis DW, McConkey DJ, Harmon D, Ryan DP, Goss G, Quigley T, Van den Abbeele AD, Silverman SG, Connors S, Folkman J, Fletcher CD, Demetri GD. Phase II study of the antiangiogenic agent SU5416 in patients with advanced soft tissue sarcomas. Clin Cancer Res 2004;10: 5732-5740.
115. Giles FJ, Stopeck AT, Silverman LR, Lancet JE, Cooper MA, Hannah AL, Cherrington JM, O'Farrell AM, Yuen HA, Louie SG, Hong W, Cortes JE, Verstovsek S, Albitar M, O'Brien SM, Kantarjian HM, Karp JE. SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes. Blood 2003;102:795-801.
116. Zangari M, Anaissie E, Stopeck A, Morimoto A, Tan N, Lancet J, Cooper M, Hannah A, Garcia-Manero G, Faderl S, Kantarjian H, Cherrington J, Albitar M, Giles FJ. Phase II study of SU5416, a small molecule vascular endothelial growth factor tyrosine kinase receptor inhibitor, in patients with refractory multiple myeloma. Clin Cancer Res 2004;10:88-95.
117. Fiedler W, Mesters R, Tinnefeld H, Loges S, Staib P, Duhrsen U, Flasshove M, Ottmann OG, Jung W, Cavalli F, Kuse R, Thomalla J, Serve H, O'Farrell AM, Jacobs M, Brega NM, Scigalla P, Hossfeld DK, Berdel WE. A phase 2 clinical study of SU5416 in patients with refractory acute myeloid leukemia. Blood 2003;102:2763-2767.
118. Lara PN, Quinn DI, Margolin K, Meyers FJ, Longmate J, Frankel P, Mack PC, Turrell C, Valk P, Rao J, Buckley P, Wun T, Gosselin R, Galvin I, Gumerlock PH, Lenz HJ, Doroshow JH, Gandara DR. SU5416 Plus interferon (alpha) in advanced renal cell carcinoma: A Phase II California Cancer Consortium Study with Biological and Imaging Correlates of Angiogenesis Inhibition. Clin Cancer Res 2003;9:4772-4781.
119. Heymach JV, Desai J, Manola J, Davis DW, McConkey DJ, Harmon D, Ryan DP, Goss D, Quigley T, Van den Abbeele AD, Silverman SG, Connors S, Folkman J, Fletcher CDM, Demetri GD. Phase II Study of the antiangiogenic agent SU5416 in patients with advanced soft tissue sarcomas. Clin Cancer Res 2004;10:5732-5740.
120. Peterson AC, Swiger S, Stadler WM, Medved M, Karczmar G, Gajewski TF. Phase II study of the Flk-1 tyrosine kinase inhibitor SU5416 in advanced melanoma. Clin Cancer Res 2004;10:4048-4054.
121. Stadler WM, Cao D, Vogelzang NJ, Ryan CW, Hoving K, Wright R, Karrison T, Vokes EE. A randomized Phase II trial of the antiangiogenic agent SU5416 in hormone-refractory prostate cancer. Clin Cancer Res 2004;10:3365-3370.
122. Laird AD, Vajkoczy P, Shawver LK, Thurnher A, Liang C, Mohammadi M, Schessinger J, Ullrich A, Hubbard SR, Blake RA, Fong TA, Strawn LM, Sun L, Tang C, Hawtin R, Tang F, Shenoy N, Hirth KP, McMahon G, Cherrington JM. SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors. Cancer Res 2000;60:4152-4160.
123. Laird AD, Christensen JG, Li G, Carver J, Smith K, Xin X, Moss KG, Louie SG, Mendel DB, Cherrington JM. SU6668 inhibits Flk-1/KDR and PDGFRbeta in vivo, resulting in rapid apoptosis of tumor vasculature and tumor regression in mice. FASEB J 2002;16:681-690.
124. Shaheen RM, Tseng WW, Davis DW, Liu W, Reinmuth N, Vellagas R, Wieczorek AA, Ogura Y, McConkey DJ, Drazan KE, Bucana CD, McMahon G, Ellis LM. Tyrosine kinase inhibition of multiple angiogenic growth factor receptors improves survival in mice bearing colon cancer liver metastases by inhibition of endothelial cell survival mechanisms. Cancer Res 2001;61:1464-1468.
125. Garofalo A, Naumova E, Manenti L, Ghilardi C, Ghisleni G, Caniatti M, Colombo T, Cherrington JM, Scanziani E, Nicoletti MI, Giavazzi R. The combination of the tyrosine kinase receptor inhibitor SU6668 with paclitaxel affects ascites formation and tumor spread in ovarian carcinoma xenografts growing orthotopically. Clin Cancer Res 2003;9:3476-3485.
126. Fabbro D, Manley PW. Su-6668. Curr Opin Investig Drugs 2001;2:1142-1148.
127. Rosen LS, Rosen PJ, Kabbinavar F, Rosen P, Cropp G, Hannah A. Phase I experience with SU6668, a novel multiple receptor tyrosine kinase inhibitor in patients with advanced malignancies. Proc Am Soc Clin Oncol 2001;20:97a.
128. Britten CD, Rosen LS, Kabbinavar F, Rosen P, Mulay M, Hernandez L, Brown J, Bello C, Kelsey SM, Scigalla P. Phase I trial of SU6668, a small molecule receptor tyrosine kinase inhibitor, given twice daily in patients with advanced cancers. Proc Am Soc Clin Oncol 2002;21:28b.
129. Demetri GD, Desai J, Fletcher JA, Morgan JA, Fletcher CDM, Kazanovicz A, Van Den Abbeele A, Baum C, Maki R, Heinrich MC. SU11248, a multi-targeted tyrosine kinase inhibitor, can overcome imatinib (IM) resistance caused by diverse genomic mechanisms in patients (pts) with metastatic gastrointestinal stromal tumor (GIST). J Clin Oncol 2004;22:3001.
130. Mendel DB, Laird AD, Xin X, Louie SG, Christensen JG, Li G, Schreck RE, Abrams TJ, Ngai TJ, Lee LB, Murray LJ, Carver J, Chan E, MoS KG, Haznedar JO, Sukbuntherng J, Blake RA, Sun C, Tang C, Miller T, Shirazian S, McMahon G, Cherrington JM. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: Determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003;9:327-337.
131. O'Farrell AM, Abrams TJ, Yuen HA, Ngai TJ, Louie SG, Yee KWH, Wong LM, Hong WM, Lee LB, Town A, Smolich BD, Manning WC, Murray LJ, Heinrich MC, Cherrington JM. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 2003;101:3597-3605.
132. Abrams TJ, Murray LJ, Pesenti E, Holway VW, Colombo T, Lee LB, Cherrington JM, Pryer NK. Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with "standard of care" therapeutic agents for the treatment of breast cancer. Mol Cancer Ther 2003;2:1011-1021.
133. Murray LJ, Abrams TJ, Long KR, Ngai TJ, Olson LM, Hong W, Keast PK, Brassard JA, O'Farrell AM, Cherrington JM, Pryer NK. SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model. Clin Exp Metastasis 2003;20:757-766.
134. Schueneman AJ, Himmelfarb E, Geng L, Tan J, Donnelly E, Mendel D, McMahon G, Hallahan DE. SU11248 maintenance therapy prevents tumor regrowth after fractionated irradiation of murine tumor models. Cancer Res 2003;63:4009-4016.
135. Yee KW, Schittenhelm M, O'Farrell AM, Town AR, McGreevey L, Bainbridge T, Cherrington JM, Heinrich MC. Synergistic effect of SU11248 with cytarabine or daunorubicin on FLT3 ITD-positive leukemic cells. Blood 2004;104:4202-4209.
136. Fiedler W, Serve H, Dohner H, Schwittay M, Ottmann OG, O'Farrell AM, Bello CL, Allred R, Manning WC, Cherrington JM, Louie SG, Hong W, Brega NM, Massimini G, Scigalla P, Berdel WE, Hossfeld DK. A phase I study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease. Blood 2005;105:986-993.
137. Motzer RJ, Rini BI, Michaelson MD, Redman BG, Hudes GR, Wilding G, Figlin RA, Zhu J, Kim ST, Baum C. SU011248, a novel tyrosine kinase inhibitor, shows antitumor activity in second-line therapy for patients with metastatic renal cell carcinoma: Results of a phase 2 trial. J Clin Oncol (Meeting Abstracts) 2004;22:4500.
138. Motzer RJ, Rini BI, Michaelson MD, Redman BG, Hudes GR, Wilding G, Bukowski RM, George DJ, Kim ST, Baum CM. Phase 2 trials of SU11248 show antitumor activity in second-line therapy for patients with metastatic renal cell carcinoma (RCC). J Clin Oncol (Meeting Abstracts) 2005;23:4508.
139. Beaumont J, Cella D, Li J, Motzer R, Rini B, Michaelson D, Kim S, Baum C. Patient reported outcomes in a phase 2 trial of SU11248 for metastatic renal cell carcinoma. J Clin Oncol (Meeting Abstracts) 2005;23:8167.
140. Demetri GD, George S, Heinrich MC, Fletcher JA, Fletcher CM, Desai J, Cohen DP, Scigalla P, Cherrington JM, Van Den Abbeele AD. Clinical activity and tolerability of the multi-targeted tyrosine kinase inhibitor SU11248 in patients (pts) with metastatic gastrointestinal stromal tumor (GIST) refractory to imatinib mesylate. Proc Am Soc Clin Oncol 2003;22: Abstract 3273.
141. Maki RG, Fletcher JA, Heinrich MC, Morgan JA, George S, Desai J, Scheu K, Fletcher CDM, Baum C, Demetri GD. Results from a continuation trial of SU11248 in patients (pts) with imatinib (IM)-resistant gastrointestinal stromal tumor (GIST). J Clin Oncol (Meeting Abstracts) 2005;23:9011.
142. Demetri GD, van Oosterom AT, Blackstein M, Garrett C, Shah M, Heinrich M, McArthur G, Judson I, Baum CM, Casali PG. Phase 3, multicenter, randomized, double-blind, placebo-controlled trial of SU11248 in patients (pts) following failure of imatinib for metastatic GIST. J Clin Oncol (Meeting Abstracts) 2005;23:4000.
143. Miller KD, Burstein HJ, Elias AD, Rugo HS, Cobleigh MA, Pegram MD, Eisenberg PD, Collier M, Adams BJ, Baum CM. Phase II study of SU11248, a multitargeted receptor tyrosine kinase inhibitor (TKI), in patients (pts) with previously treated metastatic breast cancer (MBC). J Clin Oncol (Meeting Abstracts) 2005;23:563.
144. Kulke M, Lenz HJ, Meropol NJ, Posey J, Ryan DP, Picus J, Bergsland E, Stuart K, Baum CM, Fuchs CS. A phase 2 study to evaluate the efficacy and safety of SU11248 in patients (pts) with unresectable neuroendocrine tumors (NETs). J Clin Oncol (Meeting Abstracts) 2005;23:4008.
145. Wood JM, Bold G, Buchdunger E, Cozens R, Ferrari S, Frei J, Hofmann F, Mestan J, Mett H, O'Reilly T, Persohn E, Rosel J, Schnell C, Stover D, Theuer A, Towbin H, Wenger F, Woods-Cook K, Menrad A, Siemeister G, Schirner M, Thierauch KH, Schneider MR, Drevs J, Martiny-Baron G, Totzke F. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res 2000;60:2178-2189.
146. Solorzano CC, Baker CH, Bruns CJ, Killion JJ, Ellis LM, Wood J, Fidler IJ. Inhibition of growth and metastasis of human pancreatic cancer growing in nude mice by PTK 787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases. Cancer Biother Radiopharm 2001;16:359-370.
147. Baker CH, Solorzano CC, Fidler IJ. Blockade of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling for therapy of metastatic human pancreatic cancer. Cancer Res 2002; 62:1996-2003.
148. Drevs J, Mross K, Fuxius S. A phase-1 dose-escalating and pharmacokinetic (PK) study of the VEGF-receptor-inhibitor PTK787/ZK 222584 (PTK/ZK) in patients with liver metastasis of advanced cancer. Proc Am Soc Clin Oncol 2001;20:100a.
149. Morgan B, Thomas AL, Drevs J, Hennig J, Buchert M, Jivan A, Horsfield MA, Mross K, Ball HA, Lee L, Mietlowski W, Fuxuis S, Unger C, O'Byrne K, Henry A, Cherryman GR, Laurent D, Dugan M, Marme D, Steward WP. Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: Results from two phase I studies. J Clin Oncol 2003;21:3955-3964.
150. Steward WP, Thomas A, Morgan B, Wiedenmann B, Bartel C, Vanhoefer U, Trarbach T, Junker U, Laurent D, Lebwohl D. Expanded phase I/II study of PTK787/ZK 222584 (PTK/ZK), a novel, oral angiogenesis inhibitor, in combination with FOLFOX-4 as first-line treatment for patients with metastatic colorectal cancer. J Clin Oncol (Meeting Abstracts) 2004;22:259.
151. Hecht JR, Trarbach T, Jaeger E, Hainsworth J, Wolff R, Lloyd K, Bodoky G, Borner M, Laurent D, Jacques C. A randomized, double-blind, placebo-controlled, phase III study in patients (Pts) with metastatic adenocarcinoma of the colon or rectum receiving first-line chemotherapy with oxaliplatin/5-fluorouracil/ leucovorin and PTK787/ZK 222584 or placebo (CONFIRM-1). J Clin Oncol (Meeting Abstracts) 2005;23:LBA3.
152. Reardon D, Friedman H, Yung WKA, Brada M, Conrad C, Provenzale J, Jackson E, Serajuddin H, Chen B, Laurent D. A phase I/II trial of PTK787/ZK 222584 (PTK/ZK), a novel, oral angiogenesis inhibitor, in combination with either temozolomide or lomustine for patients with recurrent glioblastoma multiforme (GBM). J Clin Oncol (Meeting Abstracts) 2004;22:110.
153. Wedge SR, Ogilvie DJ, Dukes M, Kendrew J, Curwen JO, Hennequin LF, Thomas AP, Stokes ES, Curry B, Richmond GH, Wadsworth PF. ZD4190: An orally active inhibitor of vascular endothelial growth factor signaling with broad-spectrum antitumor efficacy. Cancer Res 2000;60:970-975.
154. Wedge SR, Ogilvie DJ, Dukes M, Kendrew J, Chester R, Jackson JA, Boffey SJ, Valentine PJ, Curwen JO, Musgrove HL, Graham GA, Hughes GD, Thomas AP, Stokes ES, Curry B, Richmond GH, Wadsworth PF, Bigley AL, Hennequin LF ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res 2002;62:4645-4655.
155. Williams KJ, Telfer BA, Brave S, Kendrew J, Whittaker L, Stratford IJ, Wedge SR. ZD6474, a potent inhibitor of vascular endothelial growth factor signaling, combined with radiotherapy: Schedule-dependent enhancement of antitumor activity. Clin Cancer Res 2004;10:8587-8593.
156. Ciardiello F, Caputo R, Damiano V, Caputo R, Troiani T, Vitagliano D, Carlomagno F, Veneziani BM, Fontanini G, Bianco AR, Tortora G. Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase. Clin Cancer Res 2003;9:1546-1556.
157. Taguchi F, Koh Y, Koizumi F, Tamura T, Saijo N, Nishio K. Anticancer effects of ZD6474, a VEGF receptor tyrosine kinase inhibitor, in gefitinib ("Iressa")-sensitive and resistant xenograft models. Cancer Sci 2004;95:984-989.
158. Minami H, Ebi H, Tahara M, Sasaki Y, Yamamoto N, Yamada Y, Tamura T, Saijo N. A phase I study of an oral VEGF receptor tyrosine kinase inhibitor ZD6474, in Japanese patients with solid tumors. Proc Am Soc Clin Oncol 2003;22: Abstract 778.
159. Hurwitz H, Holden SN, Eckhardt SG, Rosenthal M, de Boer R, Rischin D, Green M, Basser R. Clinical evaluation of ZD6474, an orally active inhibitor of VEGF signaling, in patients with solid tumors. Proc Am Soc Clin Oncol 2002;22: Abstract 325.
160. Heymach JV, Johnson BE, Rowbottom JA, Fidias P, Lu C, Prager D, Roubec J, Csada E, Dimery I, Herbst RS. A randomized, placebo-controlled phase II trial of ZD6474 plus docetaxel, in patients with NSCLC. J Clin Oncol (Meeting Abstracts) 2005;23:3023.
161. Johnson BE, Ma P, West H, Kerr R, Prager D, Sandler A, Herbst RS, Stewarl DJ, Dimery IW, Heymach JV. Preliminary phase II safety evaluation of ZD6474, in combination with carboplatin and paclitaxel, as 1st-line treatment in patients with NSCLC. J Clin Oncol (Meeting Abstracts) 2005;23:7102.
162. Wilhelm S, Chien DS. BAY 43-9006: Preclinical data. Curr Pharm Des 2002;8:2255-2257.
163. Lyons JF, Wilhelm S, Hibner B, Bollag G. Discovery of a novel Raf kinase inhibitor. Endocr Relat Cancer 2001;8:219-225.
164. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, Cao Y, Shujath J, Gawlak S, Eveleigh D, Rowley B, Liu L, Adnane L, Lynch M, Auclair D, Taylor I, Gedrich R, Voznesensky A, Riedl B, Post LE, Bollag G, Trail PA. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004;64:7099-7109.
165. Strumberg D, Voliotis D, Moeller JG, Hilger RA, Richly H, Kredtke S, Beling C, Scheulen ME, Seeber S. Results of phase I pharmacokinetic and pharmacodynamic studies of the Raf kinase inhibitor BAY 43-9006 in patients with solid tumours. Int J Clin Pharmacol Ther 2002;40:580-581.
166. Richly H, Kupsch P, Passage K, Grubert M, Hilger RA, Voigtmann R, Schwartz B, Brendel E, Christensen O, Haase CG, Strumberg D. Results of a phase I trial of BAY 43-9006 in combination with doxorubicin in patients with primary hepatic cancer. Int J Clin Pharmacol Ther 2004;42:650-651.
167. Awada A, Hendlisz A, Gil T, Bartholomeus S, Mano M, de Valeriola D, Strumberg D, Brendel E, Haase CG, Schwartz B, Piccart M. Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours. Br J Cancer 2005;92:1855-1861.
168. Flaherty KT, Redlinger M, Schuchter LM, Lathia CD, Weber BL, O'Dwyer PJ. Phase I/II, pharmacokinetic and pharmacodynamic trial of BAY 43-9006 alone in patients with metastatic melanoma. J Clin Oncol (Meeting Abstracts) 2005;23:3037.
169. Rosner GL, Stadler W, Ratain MJ. Randomized discontinuation design: Application to cytostatic antineoplastic agents. J Clin Onc 2002;20:4478-4484.
170. Ratain MJ, Flaherty KT, Stadler WM, O'Dwyer P, Kaye S, Xiong H, Patnaik A, Gore M, Lee RJ, Eisen T. Preliminary antitumor activity of BAY 43-9006 in metastatic renal cell carcinoma and other advanced refractory solid tumors in a phase II randomized discontinuation trial (RDT). J Clin Oncol (Meeting Abstracts) 2004;22:4501.
171. Ratain MJ, Eisen T, Stadler WM, Flaherty KT, Gore M, Desai A, Patnaik A, Xiong HQ, Schwartz B, O'Dwyer P. Final findings from a phase II, placebo-controlled, randomized discontinuation trial (RDT) of sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC). J Clin Oncol (Meeting Abstracts) 2005;23:4544.
172. Escudier B, Szczylik C, Eisen T, Stadler WM, Schwartz B, Shan M, Bukowski RM. Randomized phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC). J Clin Oncol (Meeting Abstracts) 2005;23:LBA4510.
173. Ciardiello F, Tortora G. A novel approach in the treatment of cancer: Targeting the epidermal growth factor receptor. Clin Cancer Res 2001;7:2958-2970.
174. Kim ES, Khuri FR, Herbst RS. Epidermal growth factor receptor biology (IMC-C225). Curr Opin Oncol 2001;13:506-513.
175. Luwor RB, Lu Y, Li X, Mendelsohn J, Fan Z. The antiepidermal growth factor receptor monoclonal antibody cetuximab/C225 reduces hypoxia-inducible factor-1 alpha, leading to transcriptional inhibition of vascular endothelial growth factor expression. Oncogene 2005;24:4433-4441.
176. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Van Cutsem E. 2003. Cetuximab (C225) alone or in combination with irinotecan (CPT-11) in patients with epidermal growth factor receptor (EGFR)-positive, irinotecan-refractory metastatic colorectal cancer. Proc Am Soc Clin Oncol 2002;22:252.
177. Chan AT, Hsu MM, Goh BC, Hui EP, Liu TW, Millward MJ, Hong RL, Whang-Peng J, Ma BB, To KF, Mueser M, Amellal N, Lin X, Chang AY. Multicenter, Phase II Study of cetuximab in combination with carboplatin in patients with recurrent or metastatic nasopharyngeal carcinoma. J Clin Oncol 2005;23: 3568-3576.
178. Gunnett K, Motzer R, Amato R, Todd M, Poo W-J, Cohen R, Baselga J, Cooper M, Robert F, Falcey J, Waksal H. Phase II study of anti-epidermal growth factor receptor (EGFr) antibody C225 alone in patients (pts) with metastatic renal cell carcinoma (RCC). Proc Am Soc Clin Oncol 1999;19:389.
179. Bonner JA, Ezekiel MP, Robert F, Meredith RF, Spencer SA, Waksal HW. Continued response following treatment with IMC-225, an EGFr MoAb, combined with RT in advanced head and neck malignancies. Proc Am Soc Clin Oncol 2000;19:4.
180. Hong WK, Arquette M, Nabell L, Needle MN, Waksal HW, Herbst RS. Efficacy and safety of the anti-epidermal growth factor receptor antibody (EGFR) IMC-C225 in combination with cisplatin in patients with recurrent squamous cell carcinoma of the head and neck (SCCHN) refractory to cisplatin containing chemotherapy. Proc Am Soc Clin Oncol 2001;21:224.
181. Gatzemeier U, Pluzanska A, Szczesna A, Kaukel E, Roubec J, Brennscheidt U, De Rosa F, Mueller B, von Pawel J. Results of a phase III trial of erlotinib (OSI-774) combined with cisplatin and gemcitabine (GC) chemotherapy in advanced non-small cell lung cancer (NSCLC). J Clin Oncol (Meeting Abstracts) 2004;22:617.
182. Van Laethem J-L, Raoul J-L, Mitry E, Brezault C, Husseini F, Cals L, Vedovato JC, Mueser MM, Rougier P. Cetuximab (C225) in combination with bi-weekly irinotecan (CPT-11), infusional 5-fluorouracil (5-FU), and folinic acid (FA) in patients with metastatic colorectal cancer (CRC) expressing the epidermal growth factor receptor (EGFR). Preliminary safety and efficacy results. Proc Am Soc Clin Oncol 2003; 22:264.
183. Abbruzzese JL, Rosenberg A, Xiong Q, LoBuglio A, Schmidt W, Wolff R, Needle M, Waksal H. Phase II study of anti-epidermal growth factor receptor (EGFR) antibody cetuximab (IMC-C225) in combination with gemcitabine in patients with advanced pancreatic cancer. Proc Am Soc Clin Oncol 2001;21:130.
184. Bonner JA, Giralt J, Harari PM, Cohen R, Jones C, Sur RK, Rabin D, Azarnia N, Needle MN, Ang KK. Cetuximab prolongs survival in patients with locoregionally advanced squamous cell carcinoma of head and neck: A phase III study of high dose radiation therapy with or without cetuximab. J Clin Oncol (Meeting Abstracts) 2004;22:5507.
185. Polikoff J, Mitchell EP, Badarinath S, Graham CD, Jennis A, Chen TT, Gustafson TN, Langer C. Cetuximab plus FOLFOX for colorectal cancer (EXPLORE): Preliminary efficacy analysis of a randomized phase III trial. J Clin Oncol (Meeting Abstracts) 2005;23:3574.
186. Sobrero A, Scheithauer W, Maurel J, Mineur L, Fehrenbacher L, Kisker O, Kopit J, Langer C, Schlichting M, Abubakr Y. Cetuximab plus irinotecan for metastatic colorectal cancer (mCRC): Safety analysis of the first 400 patients in a randomized phase III trial (EPIC). J Clin Oncol (Meeting Abstracts) 2005;23:3580.
187. Lilenbaum R, Bonomi P, Ansari R, Lynch T, Govindan R, Janne P, Hanna N. A phase II trial of cetuximab as therapy for recurrent non-small cell lung cancer (NSCLC): Final results. J Clin Oncol (Meeting Abstracts) 2005;23:7036.
188. Werner-Wasik M, Swann S, Curran W, Robert F, Komaki R, Lee CP, Jafar S, Share R, Choy H, Blumenschein G. A phase II study of cetuximab (C225) in combination with chemoradiation (CRT) in patients (PTS) with stage IIIA/B non-small cell lung cancer (NSCLC): An interim overall toxicity report of the RTOG 0324 Trial. J Clin Oncol (Meeting Abstracts) 2005;23:7135.
189. Aghajanian C, Sabbatini P, Derosa F, Gerst S, Spriggs DR, Dupont J, Hensley ML, Pezzulli S, Konner J, Schilder RJ. A phase II study of cetuximab/paclitaxel/carboplatin for the initial treatment of advanced stage ovarian, primary peritoneal, and fallopian tube cancer. J Clin Oncol (Meeting Abstracts) 2005; 23:5047.
190. Tiseo M, Loprevite M, Ardizzoni A. Epidermal growth factor receptor inhibitors: A new prospective in the treatment of lung cancer. Curr Med Chem Anti-Cane Agents 2004;4:139-148.
191. Cella D, Natale RB, Lynch TJ, Lee C, Carbone D, Douillard JY, Kay A, Wolf M, Heyes A, Ward J. Disease-related symptoms in advanced non-small cell lung cancer (NSCLC) as measured by the Lung Cancer Subscale (LCS) of the FACT-L questionnaire: Clinically meaningful improvements with gefitinib (IRESSA, ZD 1839). Proc Am Soc Clin Oncol 2003;22:629.
192. Cho CD, Fisher GA, Halsey J, Jambalos CN, Advani RH, Wakelee H, Lum BL, Sikic BI. A II study of gefitinib (ZD 1839, Iressa™) combination with Folfox-4 (IFOX) in patients with unresectable or metastatic colorectal cancer. Proc Am Soc Clin Oncol 2003;22:265.
193. Cortes-Funes H, Soto-Parra H. Extensive experience of disease control with gefitinib and the role of prognostic markers. Br J Cancer 2003;89:S3-S8.
194. Cohen EE, Rosen F, Stadler WM, Recant W, Stenson K, Huo D, Vokes EE. Phase II trial of ZD 1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 2003;21:1980-1987.
195. Lieberman FS, Cloughesy T, DeAngelis L, Fine H, Fink K, Junck L, Kuhn J, Mehta M, Wen P, Prados M. Phase I-II study of ZD-1839 for recurrent malignant gliomas and meningiomas progressing after radiation therapy. Proc Am Soc Clin Oncol 2003;22: Abstract 421.
196. Ranson M, Wardell S. Gefitinib, a novel, orally administered agent for the treatment of cancer. J Clin Pharm Ther 2004;29:95-103.
197. Peery TS, Reardon DA, Quinn J, Ochs J, Wikstrand C, Stenzel TT, Bigner DD, Friedman HS, Rich JN, Dancey J. Phase II trial of ZD 1839 (Iressa) for patients with first relapse glioblastoma. Proc Am Soc Clin Oncol 2003;22: Abstract 396.
198. Robertson JFR, Gutteridge E, Cheung K, Owers R, Koehler M, Hamilton L, Gee J, Nicholson RI. Gefitinib ('Iressa', ZD 1839) is active in acquired tamoxifen (TAM)-resistant oestrogen receptor (ER)-positive and ER-negative breast cancer: Results from a Phase II study. Proc Am Soc Clin Oncol 2003;22: Abstract 23.
199. Janne PA, Gurubhagavutula S, Yeap BY, Lucca J, Ostler P, Skarin AT, Fidias P, Lynch TJ, Johnson BE. Outcomes of patients with advanced non-small cell lung cancer treated with gefitinib (ZD 1839, 'Iressa') on an expanded access study. Lung Cancer 2004;44:221-230.
200. Rich JN, Reardon DA, Peery T, Dowell JM, Quinn JA, Penne KL, Wikstrand CJ, Van Duyn LB, Dancey JE, McLendon RE, Kao JC, Stenzel TT, Ahmed Rasheed BK, Tourt-Uhlig SE, Herndon JE II, Vredenburgh JJ, Sampson JH, Friedman AH, Bigner DD, Friedman HS. Phase II trial of gefitinib in recurrent glioblastoma. J Clin Oncol 2004;22:133-142.
201. Miller VA, Kris MG, Shah N, Patel J, Azzoli C, Gomez J, Krug LM, Pao W, Rizvi N, Pizzo B, Tyson L, Venkatraman E, Ben-Porat L, Memoli N, Zakowski M, Rusch V, Heelan RT. Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. J Clin Oncol 2004;22:1103-1109.
202. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-2139.
203. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, Fujii Y, Eck MJ, Sellers WR, Johnson BE, Meyerson M. EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 2004;304:1497-500.
204. Pao W, Miller VA. Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: Current knowledge and future directions. J Clin Oncol 2005;23:2556-2568.
205. Shepherd F, Pereira J, Ciuleanu TE, Tan EH, Hirsh V, Thongprasert S, Bezjak A, Tu D, Santabarbara P, Seymour L. A randomized placebo-controlled trial of erlotinib in patients with advanced non-small cell lung cancer (NSCLC) following failure of 1st line or or 2nd line chemotherapy. A National Cancer Institute of Canada Clinical Trials Group (NCIC). J Clin Oncol (Meeting Abstracts) 2004;22:7022.
206. Moore MJ, Goldstein D, Hamm J, Kotecha J, Gallinger S, Au HJ, Nomikos D, Ding K, Ptaszynski M, Parulekar W. A Phase III double blind trial of gemcitabine ± erlotinib in locally advanced/metastatic pancreatic carcinoma. ASCO Gastrointest Cancers Symp 2005: Abstract 77.
207. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht J, Gallinger S, Au H, Ding K, Christy-Bittel J, Parulekar W. Erlotinib plus gemcitabine compared to gemcitabine alone in patients with advanced pancreatic cancer. A phase III trial of the National Cancer Institute of Canada Clinical Trials Group [NCIC-CTG]. J Clin Oncol (Meeting Abstracts) 2005;23:1.
208. Grunwald V, Hidalgo M. Development of the epidermal growth factor receptor inhibitor Tarceva (OSI-774). Adv Exp Med Biol 2003;532:235-246.
209. Sandler A. Clinical experience with the HER1/EGFR tyrosine kinase inhibitor erlotinib. Oncology 2003;11:17-22.
210. Soulieres D, Senzer NN, Vokes EE, Hidalgo M, Agarwala SS, Siu LL. Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol 2004;22:77-85.
211. Kim ES, Kies M, Sabichi A, Ginsberg L, Burke B, Holsinger C, Feng L, Truong MT, Glisson B, Hong WK. Phase II study of combination cisplatin, docetaxel and erlotinib in patients with metastatic/recurrent head and neck squamous cell carcinoma (HNSCC). J Clin Oncol (Meeting Abstracts) 2005;23:5546.
212. Felip E, Rojo F, Heller A, Foernzler D, Valverde C, Klughammer B, Ramos J, Maacke H, Brennscheidt U, Baselga J. Phase II pharmacodynamic trial of erlotinib in advanced non-small cell lung cancer (NSCLC) patients previously treated with platinum-based chemotherapy: preliminary results. J Clin Oncol (Meeting Abstracts) 2005;23:7100.
213. Giaccone G, Lechevalier T, Thatcher N, Smit E, Janmaat M, Rodriguez J, Oulid-Aissa D, Soria JC. A phase II study of erlotinib as first-line treatment of advanced non-small cell lung cancer. J Clin Oncol (Meeting Abstracts) 2005;23:7073.
214. Jackman D, Lucca J, Fidias P, Rabin MS, Lynch TJ, Ostler P, Skarin AT, Temel J, Johnson BE, Janne PA. Phase II study of the EGFR tyrosine kinase erlotinib in patients 70 years of age with previously untreated advanced non-small cell lung carcinoma. J Clin Oncol (Meeting Abstracts) 2005;23:7148.
215. Brewer CJ, Suh JH, Stevens GHJ, Barnett GH, Toms S, Vogelbaum MA, Weil R, Peereboom DM. Phase II trial of erlotinib with temozolomide and concurrent radiation therapy in patients with newly-diagnosed glioblastoma multiforme. J Clin Oncol (Meeting Abstracts) 2005;23:1567.
216. Cloughesy T, Yung A, Vrendenberg J, Aldape K, Eberhard D, Prados M, Vandenberg S, Klencke B, Mischel P. Phase II study of erlotinib in recurrent GBM: Molecular predictors of outcome. J Clin Oncol (Meeting Abstracts) 2005;23:1507.
217. Graham DL, Hillman DW, Hobday TJ, Rousey SR, Nair SG, Soori GS, Sabagh TM, Perez EA. N0234: Phase II study of erlotinib (OSI-774) plus gemcitabine as first-or second-line therapy for metastatic breast cancer (MBC). J Clin Oncol (Meeting Abstracts) 2005;23:644.
218. Spigel DR, Hainsworth JD, Sosman JA, Raefsky EL, Meluch AA, Edwards D, Horowitz P, Thomas K, Yost K, Stagg MP, Greco FA. Bevacizumab and erlotinib in the treatment of patients with metastatic renal carcinoma (RCC): Update of a phase II multicenter trial. J Clin Oncol (Meeting Abstracts) 2005;23:4540.
219. Teicher BA, Menon K, Alvarez E, Galbreath E, Shih C, Faul MM. Antiangiogenic and antitumor effects of a protein kinase C beta inhibitor in human HT-29 colon carcinoma and human CaKi1 renal cell carcinoma xenografts. Anticancer Res 2001;21:3175-3184.
220. Teicher BA, Menon K, Alvarez E, Galbreath E, Shih C, Faul MM. Antiangiogenic and antitumor effects of a protein kinase C beta inhibitor in murine lewis lung carcinoma and human Calu-6 non-small-cell lung carcinoma xenografts. Cancer Chemother Pharmacol 2001;48:473-480.
221. Teicher BA, Menon K, Alvarez E, Liu P, Shih C, Faul MM. Antiangiogenic and antitumor effects of a protein kinase C beta inhibitor in human hepatocellular and gastric cancer xenografts. In Vivo 2001;15:185-193.
222. Teicher BA, Alvarez E, Menon K, Esterman MA, Considine E, Shih C, Faul MM. Antiangiogenic effects of a protein kinase C beta-selective small molecule. Cancer Chemother Pharmacol 2002;49:69-77.
223. Teicher BA, Menon K, Alvarez E, Shih C, Faul MM. Antiangiogenic and antitumor effects of a protein kinase C beta inhibitor in human breast cancer and ovarian cancer xenografts. Invest New Drugs 2002;20:241-251.
224. Herbst RS, Thornton DE, Kies MS, Sinha V, Flanagan S, Cassidy CA, Carducci MA. Phase 1 study of LY317615, a protein kinase C inhibitor (abstract 326). Proc Am Assoc Clin Oncol 2002;21: Abstract 326.
225. Ingber D, Fujita T, Kishimoto S, Sudo K, Kanamaru T, Brem H, Folkman J. Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth. Nature 1990;348:555-557.
226. Rodriguez-Nieto S, Medina MA, Quesada AR. A re-evaluation of fumagillin selectivity towards endothelial cells. Anticancer Res 2001;21:3457-3460.
227. Abe J, Zhou W, Takuwa N, Taguchi J, Kurokawa K, Kumada M, Takuwa Y. A fumagillin derivative angiogenesis inhibitor, AGM-1470, inhibits activation of cyclin-dependent kinases and phosphorylation of retinoblastoma gene product but not protein tyrosyl phosphorylation or protooncogene expression in vascular endothelial cells. Cancer Res 1994;54:3407-3412.
228. Griffith EC, Su Z, Turk BE, Chen S, Chang YH, Wu Z, Biemann K, Liu JO. Methionine aminopeptidase (type 2) is the common target for angiogenesis inhibitors AGM-1470 and ovulicin. Chem Biol 1997;4:461-471.
229. Bergers G, Javaherian K, Lo K.-M, Forkman J, Hanahan D. Effects of angiogenesis inhibitors on multistage earcinogenesis in mice. Science 1999;284:808-812.
230. Lund EL, Bastholm L, Krisjansen PEG. Therapeutic synergy of TNP-470 and Ionizing radiation: Effects on tumor growth, vessel morphology, and angiogenesis in human glioblastoma multiforme xenographs. Clin Cancer Res 2000;6:971-978.
231. Satchi-Fainaro R, Puder M, Davies JW, Tran HT, Sampson DA, Greene AK, Corfas G, Folkman J. Targeting angiogenesis with a conjugate of HPMA copolymer and TNP-470. Nat Med 2004;10:255-261.
232. Kudelka AP, Levy T, Verschraegen CF, Edwards CL, Piamsomboon S, Termrungruanglert W, Freedman RS, Kaplan AL, Kieback DG, Meyers CA, Jaeckle KA, Loyer E, Steger M, Mante R, Mavligit G, Killian A, Tang RA, Gutterman JU, Kavanagh JJ. A phase I study of TNP-470 administered to patients with advanced squamous cell cancer of the cervix. Clin Cancer Res 1997;3:1501-1505.
233. Dezube BJ, Von Roenn JH, Holden-Wiltse J, Cheung TW, Remick SC, Cooley TP, Moore J, Sommadossi JP, Shriver SL, Suckow CW, Gill PS. Fumagillin analog in the treatment of Kaposi's sarcoma: A phase 1 AIDS clinical trial group study. AIDS clinical trial group No. 215 team. J Clin Oncol 1998;16:1444-1449.
234. Bhargava P, Marshall JL, Rizvi N, Dahut W, Yoe J, Figuera M, Phipps K, Ong VS, Kato A, Hawkins MJ. A phase I and pharmacokinetic study of TNP-470 administered weekly to patients with advanced cancer. Clin Cancer Res 1999;5:1989-1995.
235. Stadler WM, Kuzel T, Shapiro C, Sosman J, Clark J, Vogelzang NJ. Multi-institutional study of the angiogenesis inhibitor TNP-470 in metastatic renal carcinoma. J Clin Oncol 1999;17:2541-2545.
236. Herbst RS, Madden TL, Tran HT, Blumenschein GR, Meyers CA, Seabrooke LF, Khuri FR, Puduvalli VK, Allgood V, Fritsche HA, Hinton L, Newman RA, Crane EA, Fossella FV, Dordal M, Goodin T, Hong WK. Safety and pharmacokinetic effects of TNP-470, an angiogenesis inhibitor, combined with paclitaxel in patients with solid tumors: Evidence for activity in non-small-cell lung cancer. J Clin Oncol 2002;20:4440-4447.
237. Sills AK, Jr., Williams JI, Tyler BM, Epstein DS, Sipos EP, Davis JD, McLane MP, Pitchford S, Cheshire K, Gannon FH, Kinney WA, Chao TL, Donowitz M, Laterra J, Zasloff M, Brem H. Squalamine inhibits angiogenesis and solid tumor growth in vivo and perturbs embryonic vasculature. Cancer Res 1998;58:2784-2792.
238. + exchanger isoform NHE3. Am J Physiol 1999;276:C136-C144.
239. Bhargava P, Marshall JL, Dahut W, Rizvi N, Trocky N, Williams JI, Hait H, Song S, Holroyd KJ, Hawkins MJ. A phase I and pharmacokinetic study of squalamine, a novel antiangiogenic agent, in patients with advanced cancers. Clin Cancer Res 2001;7:3912-3919.
240. Herbst RS, Hammond LA, Carbone DP, Tran HT, Holroyd KJ, Desai A, Williams JI, Bekele BN, Hait H, Allgood V, Solomon S, Schiller JH. A phase I/IIA trial of continuous five-day infusion of squalamine lactate (MSI-1256F) plus carboplatin and paclitaxel in patients with advanced non-small cell lung cancer. Clin Cancer Res 2003;9:4108-4115.
241. Guba M, von Breitenbuch P, Steinbauer M, Koehl G, Flegel S, Hornung M, Bruns CJ, Zuelke C, Farkas S, Anthuber M, Jauch KW, Geissler EK. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 2002;8:128-135.
242. Vignot S, Faivre S, Aguirre D, Raymond E. MTOR-targeted therapy of cancer with rapamycin derivatives. Annals Oncol 2005;16:525-537.
243. Schuler W, Sedrani R, Cottens S, Häberlin B, Schulz M, Schuurman HJ, Zenke G, Zerwes HG, Schreier MH. SDZ RAD, a new rapamycin derivative: pharmacological properties in vitro and in vivo. Transplantation 1997;64:36-42.
244. Huang S, Houghton PJ. Inhibitors of mammalian target of rapamycin as novel antitumor agents: From bench to clinic. Curr Opin Investig Drugs 2002;3:295-304.
245. Nashan B. Early clinical experience with a novel rapamycin derivative.
246. Eisen HJ, Tuzcu EM, Dorent R, Kobashigawa J, Mancini D, Valantine-von Kaeppler HA, Starling RC, Sorensen K, Hummel M, Lind JM, Abeywickrama KH, Bernhardt P; RAD B253 Study Group. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med 2003;349:847-858.
247. Sund M, Hamano Y, Sugimoto H, Sudhakar A, Soubasakos M, Yerramalla U, Benjamin LE, Lawler J, Kieran M, Shah A, Kalluri R. Function of endogenous inhibitors of angiogenesis as endothelium-specific tumor suppressors. Proc Natl Acad Sci USA 2005;102:2934-2939.
248. O'Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA, Moses M, Lane WS, Cao Y, Sage EH, Folkman J. Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994;79:315-328.
249. O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, Flynn E, Birkhead JR, Olsen BR, Folkman J. Endostatin: An endogenous inhibitor of angiogenesis and tumor growth. Cell 1997;88:277-285.
250. Dong Z, Kumar R, Yang X, Fidler IJ. Macrophage-derived metalloelastase is responsible for the generation of angiostatin in Lewis lung carcinoma. Cell 1997;88:801-810.
251. Gately S, Twardowski P, Stack MS, Patrick M, Boggio L, Cundiff DL, Schnaper HW, Madison L, Volpert O, Bouck N, Enghild J, Kwaan HC, Soff GA. Human prostate carcinoma cells express enzymatic activity that converts human plasminogen to the angiogenesis inhibitor, angiostatin. Cancer Res 1996;56:4887-4890.
252. Sim BK. Angiostatin and endostatin: Endothelial cell-specific endogenous inhibitors of angiogenesis and tumor growth. Angiogenesis 1998;2:37-48.
253. Ren B, Wang Y, Ndebele K, Zhi Q, Chen FH, Wang YZ, Parangi S. Multiple signaling is involved in endostatin-mediated apoptosis in ECV 304 endothelial cells. Front Biosci 2005;10:1089-1097.
254. Twombly R. First clinical trials of endostatin yield lukewarm results. J Natl Cancer Inst 2002;94:1520-1521.
255. Herbst RS, Hess KR, Tran HT, Tseng JE, Mullani NA, Charnsangavej C, Madden T, Davis DW, McConkey DJ, O'Reilly MS, Ellis LM, Pluda J, Hong WK, Abbruzzese JL. Phase I study of recombinant human endostatin in patients with advanced solid tumors. J Clin Oncol 2002;20:3792-3803.
256. Dresen A, Geiger P, Pluda J, Fogler W, Schiller JH, Wilding G. Phase I pharmacokinetic and pharmacodynamic study of recombinant human endostatin in patients with advanced solid tumors. J Clin Oncol 2003;21:223-231.
257. Eder JP, Jr., Supko JG, Clark JW, Puchalski TA, Garcia-Carbonero R, Ryan DP, Shulman LN, Proper J, Kirvan M, Rattner B, Connors S, Keogan MT, Janicek MJ, Fogler WE, Schnipper L, Kinchla N, Sidor C, Phillips E, Folkman J, Kufe DW. Phase I clinical trial of recombinant human endostatin administered as a short intravenous infusion repeated daily. J Clin Oncol 2002;20:3772-3784.
258. Sun Y, Wang J, Liu Y, Song X, Zhang Y, Li K, Zhu Y, Zhou Q, You L, Yao C. Results of phase III trial of rhendostatin (YH-16) in advanced non-small cell lung cancer (NSCLC) patients. J Clin Oncol (Meeting Abstracts) 2005;23:7138.
259. De Moraes ED, Fogler WE, Grant D, Wahl M, Leeper D, Zrada S, Malin A, Connors S, Fortier AH, Dabrow M, Sidor C, Capizzi RL. Recombinant human angiostatin (rhA): A Phase I clinical trial assessing safety, pharmacokinetics (PK) and pharmacodynamics (PD). Proc Am Soc Clin Oncol 2001;20:3.
260. Beerepoot LV, Witteveen ED, Groenewegen G, Fogler WE, Sim BK, Sidar C, Zonnenberg BA, Schramel F, Gebbink MF, Voest EE. Recombinant human angiostatin by twice-daily subcutaneous injection in advanced cancer: A pharmokinetic and long-term safety study. Clin Cancer Res 2003;9:4025-4033.
261. Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin Oncol 2002;29:15-18.
262. Kisker O, Becker CM, Prox D, Fannon M, D'Amato R, Flynn E, Fogler WE, Sim BK, Allred EN, Piric-Shepherd SR, Folkman J. Continuous administration of endostatin by intraperitoneally implanted osmoticpump improves the efficacy and potency of therapy in a mouse xenograft tumor model. Cancer Res 2001;61:7669-7674.
263. Kim KS, Kim HS, Park JS, Kwon YG, Park YS. Inhibition of B16BL6 tumor progression by coadministration of recombinant angiostatin K1-3 and endostatin genes with cationic liposomes. Cancer Gene Ther 2004;11:441-449.
264. Dutour A, Monteil J, Paraf F, Charissoux JL, Kaletta C, Sauer B, Naujoks K, Rigaud M. Endostatin cDNA/Cationic liposome complexes as a promising therapy to prevent lung metastases in osteosarcoma: Study in a human-like rat orthotopic tumor. Mol Ther 2005;11:311-319.
265. Coussens LM, Fingleton B, Matrisian LM. Matrix metalloproteinase inhibitors and cancer: Trials and tribulations. Science 2002;295:2387-2392.
266. Dove A. MMP inhibitors: Glimmers of hope amidst clinical failures. Nature Med 2002;8:95.
267. Overall CM, Lopez-Otin C. Strategies for MMP inhibition in cancer: Innovations for the post-trial era. Nat Rev Cancer 2002;2:657-672.
268. Macaulay VM, O'Byrne KJ, Saunders MP, Braybrooke JP, Long L, Gleeson F, Mason CS, Harris AL, Brown P, Talbot DC. Phase I study of intrapleural batimastat (BB-94), a matrix metalloproteinase inhibitor, in the treatment of malignant pleural effusions. Clin Cancer Res 1999;5:513-520.
269. Sieward WP, Thomas AL. Marimastat: The clinical development of a matrix metalloproteinase inhibitor. Expert Opin Investig Drugs 2000;9:2913-2922.
270. Bramhall SR, Rosemurgy A, Brown PD, Bowry C, Buckels JA. Marimastat Pancreatic Cancer Study Group. Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial. J Clin Oncol 2001;19:3447-3455.
271. Shepherd FA, Giaccone G, Seymour L, Debruyne C, Bezjak A, Hirsh V, Smylie M, Rubin S, Martins H, Lamont A, Krzakowski M, Sadura A, Zee B. Prospective, randomized, double-blind, placebo-controlled trial of marimastat after response to first-line chemotherapy in patients with small-cell lung cancer: A trial of the National Cancer Institute of Canada-Clinical Trials Group and the European Organization for Research and Treatment of Cancer. J Clin Oncol 2002;20:4434-4439.
272. Sparano JA, Bernardo P, Stephenson P, Gradishar WJ, Ingle JN, Zucker S, Davidson NE. Randomized phase III trial of marimastat versus placebo in patients with metastatic breast cancer who have responding or stable disease after first-line chemotherapy: Eastern Cooperative Oncology Group trial E2196. J Clin Oncol 2004;22:4683-4690.
273. Shalinsky DR, Brekken J, Zou H, McDermott CD, Forsyth P, Edwards D, Margosiak S, Bender S, Truitt G, Wood A, Varki NM, Appelt K. Broad antitumor and antiangiogenic activities of AG3340, a potent and selective MMP inhibitor undergoing advanced oncology clinical trials. Ann N Y Acad Sci 1999;878:236-270.
274. Chantrain CF, Shimada H, Jodele S, Groshen S, Ye W, Shalinsky DR, Werb Z, Coussens LM, DeClerck YA. Stromal matrix metalloproteinase-9 (MMP-9) regulates the vascular architecture in neuroblastoma by promoting pericyte recruitment. Cancer Res 2004;64:1675-1686.
275. D'Olimpio J, Hande K, Collier M, Michelson G, Paradiso L, Clendeninn N. Phase I study of the matrix metalloproteinase inhibitor AG340 in combination with paclitaxel and carboplatin for the treatment of patients with advanced solid tumors. Proc Am Soc Clin Oncol 1999;18: Abstract 615.
276. Scatena R. Prinomastat, a hydroxamate-based matrix metalloproteinase inhibitor. A novel pharmacological approach for tissue remodelling-related diseases. Expert Opin Investig Drugs 2000;9:2159-2165.
277. Bonomi P. Matrix metalloproteinases and matrix metalloproteinase inhibitors in lung cancer. Semin Oncol 2002;29:78-86.
278. Bissett D, O'Byrne KJ, von Pawel J, Gatzemeier U, Price A, Nicolson M, Mercier R, Mazabel E, Penning C, Zhang MH, Collier MA, Shepherd FA. Phase III study of matrix metalloproteinase inhibitor prinomastat in non-small-cell lung cancer. J Clin Oncol 2005;23:842-849.
279. Smylie M, Mercier R, Aboulafia D, Tucker R, Bonomi P, Collier M, Keller MR, Stuart-Smith J, Knowles M, Clendeninn NJ, Shepherd F. Phase III study of the matrix metalloproteinases (MMP) inhibitor prinomastat in patients having advanced non-small cell lung cancer. Proc Am Soc Clin Oncol 2001;20:307a.
280. Bissett D, O'Bryne K, von Pawel J, Mercler R, Price A, Nicolson M, Shepherd F, Mazabel E, Penning C, Zhang MH, Collier MA. Phase III study of the matrix metalloprotease inhibitor prinomastat in combination with gemcitibine and cisplatin in non-small cell lung cancer. Proc Am Soc Clin Oncol 2002;2l:296a.
281. Behrendt CE, Ruiz RB. Venous thromboembolism among patients with advanced lung cancer randomized to prinomastat or placebo, plus chemotherapy. Thromb Haemost 2003;90:734-737.
282. Ferrario A, Chantrain CF, von Tiehl K, Buckley S, Rucker N, Shalinsky DR, Shimada H, DeClerck YA, Gomer CJ. The matrix metalloproteinase inhibitor prinomastat enhances photodynamic therapy responsiveness in a mouse tumor model. Cancer Res 2004;64:2328-2332.
283. Ozerdem U, Mach-Hotacre B, Keefe K, Pham T, Soules K, Appelt K, Freeman WR. The effect of prinomastat (AG3340), a synthetic inhibitor of matrix metalloproteinases, on posttraumatic proliferative vitreoretinopathy. Ophthalmic Res 2001;33:20-23.
284. Ozerdem U, Mach-Hofacre B, Varki N, Folberg R, Mueller AJ, Ochabski R, Pham T, Appelt K, Freeman WR. The effect of prinomastat (AG3340), a synthetic inhibitor of matrix metalloproteinases, on uveal melanoma rabbit model. Curr Eye Res 2002;24:86-91.
285. Garcia C, Bartsch DU, Rivero ME, Hagedorn M, McDermott CD, Bergeron-Lynn G, Cheng L, Appelt K, Freeman WR. Efficacy of Prinomastat) (AG3340), a matrix metalloprotease inhibitor, in treatment of retinal neovascularization. Curr Eye Res 2002;4:33-38.
286. Garcia C, Bartsch DU, Rivero ME, Hagedorn M, McDermott CD, Bergeron-Lynn G, Cheng L, Appelt K, Freeman WR. Efficacy of Prinomastat (AG3340), a matrix metalloprotease inhibitor, in treatment of retinal neovascularization. Curr Eye Res 2002;24:33-38.
287. Rowinsky EK, Humphrey R, Hammond LA, Aylesworth C, Smetzer L, Hidalgo M, Morrow M, Smith L, Garner A, Sorensen JM, Von Hoff DD, Eckhardt SG. Phase I and pharmacologic of the specific matrix metalloprotease inhibitor BAY 12-9566 on a protracted oral daily dosing schedule in patients with solid malignancies. J Clin Oncol 2000;18:178-186.
288. Heath EI, O'Reilly S, Humphrey R, Sundaresan P, Donehower RC, Sartorius S, Kennedy MJ, Armstrong DK, Carducci MA, Sorensen JM, Kumor K, Kennedy S, Grochow LB. Phase I trial of the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced solid tumors. Cancer Chemother Pharmacol 2001;48:269-274.
289. Bloomston M, Zervos EE, Rosemurgy AS. Matrix metalloproteinases and their role in pancreatic cancer: A review of preclinical studies and clinical trials. Ann Surg Oncol 2002;9:668-674.
290. Heath EI, O'Reilly S, Humphrey R, Sundaresan P, Donehower RC, Sartorius S, Kennedy MJ, Armstrong DK, Carducci MA, Sorensen JM, Kumor K, Kennedy S, Grochow LB. Phase I trial of the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced solid tumors. Cancer Chemother Pharmacol 2001;48:269-274.
291. Deplanque G, Harris AL. Anti-angiogenic agents: Clinical trial design and therapies in development. Eur J Cancer 2000;36:1713-1724.
292. Brown PD. Ongoing trials with matrix metalloproteinase inhibitors. Expert Opin Investig Drugs 2002;9:2167-2177.
293. Wall L, Talbot DC, Bradbury P, Jodrell DI. A phase I and pharmacological study of the matrix metalloproteinase inhibitor BB-3644 in patients with solid tumours. Br J Cancer 2004;90:800-804.
294. Naglich JG, Jure-Kunkel M, Gupta E, Fargnoli J, Henderson AJ, Lewin AC, Talbott R, Baxter A, Bird J, Savopoulos R, Wills R, Kramer RA, Trail PA. Inhibition of angiogenesis and metastasis in two murine models by the matrix metalloproteinase inhibitor, BMS-275291. Cancer Res 2001;61:8480-8585.
295. Lombard M, Wallace T, Kubicek MF, Petzold GL, Mitchell MA, Hendges SK, Wilks JW. Synthetic matrix metalloproteinase inhibitors and tissue inhibitor of metalloproteinase (TIMP)-2, but not TIMP-1, inhibit shedding of tumor necrosis factor receptors in a human colon adenocarcinoma (Colo 205) cell line. Cancer Res 1998;58:4001-4007.
296. Rizvi NA, Humphrey JS, Ness EA, Johnson MD, Gupta E, Williams K, Daly DJ, Sonnichsen D, Conway D, Marshall J, Hurwitz H. A phase I study of oral BMS-275291, a novel nonhydroxamate sheddase-sparing matrix metalloproteinase inhibitor, in patients with advanced or metastatic cancer. Clin Cancer Res 2004;10:1963-1970.
297. Hurwitz H, Humphrey J, Williams K, Ness E, Conway A, Lockhart AC, Bielefeld M, Tarby C, Sonnichsen D, Gupta E, Huang MQ, Mao Y, Raphael M, Daley D, Marshall J, Johnson M, Rizvi N. A phase I trial of BMS-275291: A novel non-hydrozamate, sheddase-sparing matrix metalloproteinase inhibitor with no dose-limiting arthritis. Proc Am Soc Clin Oncol 2001;20:98a.
298. Lara PN, Stadler WM, Longmate J, Quinn DI, Wexler J, Van Loan M, Twardowski P, Gumerlock PH, Vogelzang NJ, Yokes EE, Lenz HJ, Doroshow JH, Gundara DR. A randomized phase II trial of the matrix metalloproteinase inhibitor BMS-275291 in hormone-refractory prostate cancer patients with bone metastases. Clin Cancer Res 2006;12:1556-1563.
299. Poulaki V. BMS-275291. Bristol-Myers Squibb. Curr Opin Investig Drugs 2002;3:500-504.
300. Douillard JY, Peschel C, Shepherd F, Paz-Ares L, Arnold A, Davis M, Tonato M, Smylie M, Tu D, Voi M, Humphrey J, Ottaway J, Young K, Vreckem AV, Seymour L. Randomized phase II feasibility study of combining the matrix metalloproteinase inhibitor BMS-275291 with paclitaxel plus carboplatin in advanced non-small cell lung cancer. Lung Cancer 2004;46:361-368.
301. Leighl NB, Paz-Ares L, Douillard JY, Peschel C, Arnold A, Depierre A, Santoro A, Betticher DC, Gatzemeier U, Jassem J, Crawford J, Tu D, Bezjak A. Randomized Phase III Study of Matrix Metalloproteinase Inhibitor BMS-275291 in Combination With Paclitaxel and Carboplatin in Advanced Non-Small-Cell Lung Cancer: National Cancer Institute of Canada-Clinical Trials Group Study BR. 18., Humphrey JS, Voi M, Galbraith S, Hann K, Seymour L, Shepherd FA. J Clin Oncol 2005;23:2831-2839.
302. Miller KD, Saphner TJ, Waterhouse DM, Chen TT, Rush-Taylor A, Sparano JA, Wolff AC, Cobleigh MA, Galbraith S, Sledge GW. A randomized phase II feasibility trial of BMS-275291 in patients with early stage breast cancer. Clin Cancer Res 2004;10:1971-1975.
303. Wood J, Schnell C, Cozens R. CGS27023a, a potent and orally active matrix metalloprotease inhibitor with anti-tumour activity. Proc Am Assoc Cancer Res 1998;39:83A.
304. Nakamura ES, Koizumi K, Yamaura T, Saiki I. Anti-tumor angiogenic effect of a matrix metalloproteinase inhibitor MMI270. Anticancer Res 2003;23:411-417.
305. Levitt NC, Eskens FA, O'Byrne KJ, Propper DJ, Denis LJ, Owen SJ, Choi L, Foekens JA, Wilner S, Wood JM, Nakajima M, Talbot DC, Steward WP, Harris AL, Verweij J. Phase 1 and pharmacological study of the oral matrix metalloproteinase inhibitor, MMI270 (CGS27023A), in patients with advanced solid cancer. Clin Cancer Res 2001;7:1912-1922.
306. Eatock M, Cassidy J, Johnson J, Morrison R, Devlin M, Blackey R, Owen S, Choi L, Twelves C. A dose-finding and pharmacokinetic study of the matrix metalloproteinase inhibitor MM 1270 (previously termed CGS27023A) with 5-FU and folinic acid. Cancer Chemother Pharmacol 2005;55:39-46.
307. Bramhall SR, Schulz J, Nemunaitis J, Brown PD, Baillet M, Buckels JA. A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer. Br J Cancer 2002;87:161-167.
308. Bramhall SR, Hallissey MT, Whiting J, Scholefield J, Tierney G, Stuart RC, Hawkins RE, McCulloch P, Maughan T, Brown PD, Baillet M, Fielding JW. Marimastat as maintenance therapy for patents with advanced gastric cancer: A randomised trial. Br J Cancer 2002;86:1864-1870.
309. Groves MD, Puduvalli VK, Hess KR, Jaeckle KA, Peterson P, Yung WK, Levin VA. Phase II trial of temozolomide plus the matrix metalloproteinase inhibitor, marimastat, in recurrent and progressive glioblastoma multiforme. J Clin Oncol 2002;20:1383-1388.
310. Ramnath N, Creaven PJ. Matrix metalloproteinase inhibitors. Curr Oncol Rep 2004;6:96-102.
311. Lokeshwar BL. MMP inhibition in prostate cancer. Ann N Y Acad Sci 1999;878:271-289.
312. Selzer MG, Zhu B, Block NL, Zhu B, Lokeshwar BL. CMT-3, a chemically modified tetracycline, inhibits bony metastases and delays the development of paraplegia in a rat model of prostate cancer. Ann N Y Acad Sci 1999;878:678-682.
313. Seftor RE, Seftor EA, De Larco JE, Kleiner DE, Leferson J, Stetler-Stevenson WG, McNamara TF, Golub LM, Hendrix MJ. Chemically modified tetracyclines inhibit human melanoma cell invasion and metastasis. Clin Exp Metastasis 1998;16:217-225.
314. Lokeshwar BL, Escatel E, Zhu B. Cytotoxic activity and inhibition of tumor cell invasion by derivatives of a chemically modified tetracycline CMT-3 (COL-3). Curr Med Chem 2001;8:271-279.
315. Lokeshwar BL, Selzer MG, Zhu BQ, Block NL, Golub LM. Inhibition of cell proliferation, invasion, tumor growth and metastasis by an oral non-antimicrobial tetracycline analog (COL-3) in a metastatic prostate cancer model. Int J Cancer 2002;98:297-309.
316. Rudek MA, Figg WD, Dyer V, Dahut W, Turner ML, Steinberg SM, Liewehr DJ, Kohler DR, Pluda JM, Reed E. Phase I clinical trial of oral COL-3, a matrix metalloproteinase inhibitor, in patients with refractory metastatic cancer. J Clin Oncol 2001;19:584-592.
317. Cianfrocca M, Cooley TP, Lee JY, Rudek MA, Scadden DT, Ratner L, Pluda JM, Figg WD, Krown SE, Dezube BJ. Matrix metalloproteinase inhibitor COL-3 in the treatment of AIDS-related Kaposi's sarcoma: A phase I AIDS malignancy consortium study. J Clin Oncol 2002;20:153-159.
318. Syed S, Takimoto C, Hidalgo M, Rizzo J, Kuhn JG, Hammond LA, Schwartz G, Tolcher A, Patnaik A, Eckhardt SG, Rowinsky EK. A phase I and pharmacokinetic study of Col-3 (Metastat), an oral tetracycline derivative with potent matrix metalloproteinase and antitumor properties. Clin Cancer Res 2004;10:6512-6521.
319. Gingras D, Renaud A, Mousseau N, Beliveau R. Shark cartilage extracts as antiangiogenic agents: Smart drinks or bitter pills?. Cancer Metastasis Rev 2000;19:83-86.
320. Gingras D, Boivin D, Deckers C, Gendron S, Barthomeuf C, Beliveau R. Neovastat-a novel antiangiogenic drug for cancer therapy. Anticancer Drugs 2003;14:91-96.
321. Boivin D, Gendron S, Beaulieu E, Gingras D, Beliveau R. The antiangiogenic agent Neovastat (AE-941) induces endothelial cell apoptosis. Mol Cancer Ther 2002;1:795-802.
322. Dupont E, Falardeau P, Mousa, Dimitriadou V, Pepin MC, Wang T, Alaoui-Jamali MA. Antiangiogenic and antimetastatic properties of Neovastat (AE-941), an orally active extract derived from cartilage tissue. Clin Exp Metast 2002;19:145-153.
323. Batist G, Patenaude F, Champagne P, Croteau D, Levinton C, Hariton C, Escudier B, Dupont E. Neovastat (AE-941) in refractory renal cell carcinoma patients: Report of a phase II trial with two dose levels. Ann Oncol 2002;13:1259-1263.
324. Latreille J, Batist G, Laberge F, Champagne P, Croteau D, Falardeau P, Levinton C, Hariton C, Evans WK, Dupont E. Phase I/II trial of the safety and efficacy of AE-941 (Neovastat) in the treatment of non-small-cell lung cancer. Clin Lung Cancer 2003;4:231-236.
325. Falardeau P, Champagne P, Poyet P, Hariton C, Dupont E. Neovastat, a naturally occurring multifunctional antiangiogenic drug, in phase III clinical trials. Semin Oncol 2001;28:620-625.
326. Bukowski RM. AE-941, a multifunctional antiangiogenic compound: Trials in renal cell carcinoma. Expert Opin Investig Drugs 2003;12:1403-1411.
327. Dredge K. AE-941 (AEterna). Curr Opin Investig Drugs 2004;5:668-677.
328. Escudier B, Venner P, Buckowski R, Szczylik C, Oudard S, Champagne P, Hariton C, Dupont E. Phase III trial of neovastat in metastatic renal cell carcinoma patients refractory to immunotherapy. Proc Am Soc Clin Oncol 2003;22:211.
329. Lu C, Komaki R, Herbst RS, Evans WK, Lee JJ, Truong M, Moore CA, Choy H, Bleyer A, Fisch MJ. A phase III study of AE-941 with induction chemotherapy (IC) and concomitant chemoradiotherapy (CRT) for stage III non-small cell Lung cancer (NSCLC) (NCI T99-0046, RTOG 02-70, MDA 99-303): An interim report of toxicity and response. J Clin Oncol (Meeting Abstracts) 2005;23:7144.
330. Sauder DN, Dekoven J, Champagne P, Croteau D, Dupont E. Neovastat (AE-941), an inhibitor of angiogenesis: Randomized phase I/II clinical trial results in patients with plaque psoriasis. J Am Acad Dermatol 2002;47:535-541.
331. Thaloor D, Singh AK, Sidhu GS, Prasad PV, Kleinman HK, Maheswari RK. Inhibition of angiogenic differentiation of human umbilical endothelial cells by curcumin. Cell Growth Differ 1998;9:305-312.
332. Philip S, Kundu GC. Osteopontin induces nuclear factor kappa B-mediated promatrix metalloproteinase-2 activation through I kappa B alpha/IKK signaling pathways, and curcumin (diferulolylmethane) down-regulates these pathways. J Biol Chem 2003;278:14487-14497.
333. Elkin M, Miao HQ, Nagler A, Aingorn E, Reich R, Memo I, Dou HL, Pines M, Vlodavsky I. Halofuginone: A potent inhibitor of critical steps in angiogenesis progression. FASEB J 2000;14:2477-2485.
334. Rodriguez-Nieto S, Gonzalez-Iriarte M, Carmona R, Munoz-Chapuli R, Medina MA, Quesada AR. Antiangiogenic activity of aeroplysinin-1, a brominated compound isolated from a marine sponge. FASEB J 2001.10.1096/fj.01-0427fje, 2001a.
335. 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 1994;79:1157-1164.
336. 3 blocks human breast cancer growth and angiogenesis in human skin. J Clin Invest 1995;96:1815-1822.
337. 3-targeted magnetic resonance imaging. Nat Med 1998;4:623-626.
338. 3) antibody in patients with metastatic cancer. Cancer Biother Radiopharm 2001;16:125-132.
339. 3) integrin, ± dacarbazine (DTIC) in patients with metastatic melanoma (MM). J Clin Oncol (Meeting Abstracts) 2005;23:7507.
340. Mikecz K. Vitaxin applied molecular evolution. Curr Opin Investig Drugs 2000;1:199-203.
341. Patel SR, Jenkins J, Papadopolous N, Burgess MA, Plager C, Gutterman J, Benjamin RS. Pilot study of vitaxin-an angiogenesis inhibitor-in patients with advanced leiomyosarcomas. Cancer 2001;92:1347-1348.
342. Wilder R. Integrin alpha v beta 3 as a target for treatment of rheumatoid arthritis and related rheumatic diseases. Ann Rheum Dis 2002;61(Suppl 2):ii 96-99.
343. Mitjans F, Meyer T, Fittschen C, Goodman SL, Jonczyk A, Marshall JF, Reyes G, Piulats J. In vivo therapy of malignant melanoma by means of antagonists of v integrins. Int J Cancer 2000;87:716-723.
344. Burke PA, DeNardo SJ, Miers LA, Lamborn KR, Matzku S, DeNardo GL. Cilengitide targeting of alpha(v)beta(3) integrin receptor synergizes with radioimmunotherapy to increase efficacy and apoptosis in breast cancer xenografts. Cancer Res 2002;62:4263-4272.
345. 3 integrin antagonists. J Am Chem Soc 1996;118:7461-7472.
346. 3 integrin antagonists. J Med Chem 1999;42:3033-3040.
347. Assa-Munt N, Jia X, Laakkonen P, Ruoslahti E. Solution structures and integrin binding activities of an RGD peptide with two isomers. Biochemistry 2001;40:2373-2378.
348. Eskens FA, Dumez H, Hoekstra R, Perschl A, Brindley C, Bottcher S, Wynendaele W, Drevs J, Verweij J, van Oosterom AT. Phase 1 and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins alpha v beta 3 and alpha v beta 5 in patients with advanced solid tumours. Eur J Cancer 2003;39:917-926.
349. Raguse JD, Gath HJ, Bier J, Riess H, Oettle H. Cilengitide (EMD 121974) arrests the growth of a heavily pretreated highly vascularised head and neck tumour. Oral Oncol 2004;40:228-230.
350. Kerr JS, Wexler RS, Mousa SA, Robinson CS, Wexler EJ, Mohamed S, Voss ME, Devenny JJ, Czerniak PM, Gudzelak A, Jr., Slee AM. Novel small molecule alpha v integrin antagonists: Comparative anticancer efficacy with known angiogenesis inhibitors. Anticancer Res 1999;19:959-968.
351. Batt DG, Petraitis JJ, Houghton GC, Modi DP, Cain GA, Corjay MH, Mousa SA, Bouchard PJ. Forsythe MS, Harlow PP, Barbera FA, Spitz SM, Wexler RR, Jadhav PK. Disubstituted indazoles as potent antagonists of the integrin alpha(v)beta(3). J Med Chem 2000;43:41-58.
352. 3 (the vitronectin receptor). Drug Disc Today 2000;5:397-408.
353. Van Waes C, Enamorado-Ayala I, Hecht D, Sulica L, Chen Z, Batt DG, Mousa S. Effects of the novel alphav integrin antagonist SM256 and cis-platinum on growth of murine squamous cell carcinoma PAM LY8. Int J Oncol 2000;16:1189-1195.
354. Bourguet E, Baneres JL, Parello J, Lusinchi X, Girard JP, Vidal JP. Nonpeptide RGD antagonists: A novel class of mimetics, the 5,8-disubstituted 1-azabicyclo|5.2.0| nonan-2-one lactam. Bioorg Med Chem Lett 2003;13:1561-1564.
355. Hynes RO. A reevaluation of integrins as regulators of angiogenesis. Nat Med 2002;8:918-921.
356. Tseng S, Pak G, Washenik K, Pomeranz MK, Shupack JL. Rediscovering thalidomide: A review of its mechanism of action, side effects, and potential uses. J Am Acad Dermatol 1996;35:969-979.
357. Sheskin J. Further observation with thalidomide in lepra reactions. Lepr Rev 1965;36:183-187.
358. D'Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 1994;91:4082-4085.
359. Geitz H, Handt S, Zwingenberger K. Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade. Immunopharmacol 1996;31:213-221.
360. Yabu T, Tomimoto H, Taguchi Y, Yamaoka S, Igarashi Y, Okazaki T. Thalidomide-induced anti-angiogenic action is mediated by ceramide through depletion of VEGF receptors, and antagonized by sphingosine-1-phosphate. Blood 2005;106:125-134.
361. Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P, Munshi N, Anaissic E, Wilson C, Dhodapkar M, Zeddis J, Barlogie B. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999;341:1565-1571.
362. Durie BG, Stepan DE. Efficacy of low dose thalidomide in multiple myeloma. Elec J Oncol 2000;1:1-8.
363. Barlogie B, Desikan R, Eddlemon P, Spencer T, Zeldis J, Munshi N, Badros A, Zangari M, Anaissie E, Epstein J, Shaughnessy J, Ayers D, Spoon D, Tricot G. Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: Identification of prognostic factors in a phase 2 study of 169 patients. Blood 2000;98:492-494.
364. Fine HA, Figg WD, Jaeckle K, Wen PY, Kyritsis AP, Loeffler JS, Levin VA, Black PM, Kaplan R, Pluda JM, Yung WK. Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas. J Clin Oncol 2000;18:708-715.
365. Politi P, Reboredo G, Losso M, Vujacich C, Schwartsmann G, Lewi D. Phase I trial of thalidomide in AIDS-related Kaposi sarcoma. Proc Am Soc Clin Oncol 1999;18: Abstract 161.
366. Little RF, Wyvill KM, Pluda JM, Welles L, Marshall V, Figg WD, Newcomb FM, Tosato G, Feigal E, Steinberg SM, Whitby D, Goedert JJ, Yarchoan R. Activity of thalidomide in AIDS-related Kaposi's sarcoma. J Clin Oncol 2000;18:2593-2602.
367. Dreicer R, Klein EA, Elson P, Peereboom D, Byzova T, Plow EF. Phase II trial of GM-CSF+thalidomide in patients with androgen-independent metastatic prostate cancer. Urol Oncol 2005;23:82-86.
368. Figg WD, Arlen P, Gulley J, Fernandez P, Noone M, Fedenko K, Hamilton M, Parker C, Kruger EA, Pluda J, Dahut WL. A randomized phase II trial of docetaxel (taxotere) plus thalidomide in androgen-independent prostate cancer. Semin Oncol 2001;4:62-66.
369. Figg WD, Dahut W, Duray P, Hamilton M, Tompkins A, Steinberg SM, Jones E, Premkumar A, Linehan WM, Floeter MK, Chen CC, Dixon S, Kohler DR, Kruger EA, Gubish E, Pluda JM, Reed E. A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer. Clin Cancer Res 2001;7:1888-1893.
370. Mesa RA, Steensma DP, Pardanani A, Li CY, Elliott M, Kaufmann SH, Wiseman G, Gray LA, Schroeder G, Reeder T, Zeldis JB, Tefferi A. A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia. Blood 2003;101:2534-2541.
371. Gupta A, Cohen BH, Ruggieri P, Packer RJ, Phillips PC. Phase I study of thalidomide for the treatment of plexiform neurofibroma in neurofibromatosis 1. Neurology 2003;60:130-132.
372. Reiriz AB, Richter MF, Fernandes S, Cancela AI, Costa TD, Di Leone LP, Schwartsmann G. Phase II study of thalidomide in patients with metastatic malignant melanoma. Melanoma Res 2004;14:527-531.
373. Eisen T, Boshoff C, Mak I, Sapunar F, Vaughan MM, Pyle L, Johnston SR, Ahern R, Smith IE, Gore ME. Continuous low dose thalidomide: A phase II study in advanced melanoma, renal cell, ovarian and breast cancer. Br J Cancer 2000;82:812-817.
374. Escudier B, Lassau N, Couanet D, Angevin E, Mesrati F, Leborgne S, Garofano A, Leboulaire C, Dupouy N, Laplanche A. Phase II trial of thalidomide in renal-cell carcinoma. Ann Oncol 2002;13:1029-1035.
375. Motzer RJ, Berg W, Ginsberg M, Russo P, Vuky J, Yu R, Bacik J, Mazumdar M. Phase II trial of thalidomide for patients with advanced renal cell carcinoma. J Clin Oncol 2002;20:302-306.
376. Baidas SM, Winer EP, Fleming GF, Harris L, Pluda JM, Crawford JG, Yamauchi H, Isaacs C, Hanfelt J, Tefft M, Flockhart D, Johnson MD, Hawkins MJ, Lippman ME, Hayes DF. Phase II evaluation of thalidomide in patients with metastatic breast cancer. J Clin Oncol 2000;18:2710-2717.
377. Knisely JPS, Berkey BA, Chakravarti A, Yung WKA, Curran WJ, Robins HI, Movsas B, Brachman DG, Henderson RH, Mehta MP. RTOG 0118: A phase III study of conventional radiation therapy alone vs. conventional radiation therapy plus thalidomide for multiple brain metastases. J Clin Oncol (Meeting Abstracts) 2005;23:1500.
378. Alessandro R, Masiero L, Liotta LA, Kohn EC. The role of calcium in the regulation of invasion and angiogenesis. In Vivo 1996;10:153-160.
379. ++ influx. Biochem Biophys Res Commun 1998;248:635-640.
380. Bauer KS, Cude KJ, Dixon SC, Kruger EA, Figg WD. Carboxyamido-triazole inhibits angiogenesis by blocking the calcium-mediated nitric-oxide synthase-vascular endothelial growth factor pathway. J Pharmacol Exp Ther 2000;292:31-37.
381. Ge S, Rempel SA, Divine G, Mikkelsen T. Carboxyamido-triazole induces apoptosis in bovine aortic endothelial and human glioma cells. Clin Cancer Res 2000;6:1248-1254.
382. Kohn EC, Jacobs W, Kim YS, Alessandro R, Stetler-Stevenson WG, Liotta LA. Calcium influx modulates expression of matrix metalloproteinase-2 (72 kDa type IV collagenase, gelatinase A) expression. J Biol Chem 1994;269:21505-21511.
383. Kohn EC, Alessandro R, Spoonster J, Wersto RP, Liotta LA. Angiogenesis: Role of calcium-mediated signal transduction. Proc Natl Acad Sci USA 1995;92:1307-1311.
384. Kohn EC, Reed E, Sarosy G, Christian M, Link CJ, Cole K, Figg WD, Davis PA, Jacob J, Goldspiel B, Liotta LA. Clinical investigation of a cytostatic calcium influx inhibitor in patients with refractory cancers. Cancer Res 1996;56:569-573.
385. Kohn EC, Figg WD, Sarosy GA, Bauer KS, Davis PA, Soltis MJ, Thompkins A,
386. Kohn EC, Reed E, Sarosy GA, Minasian L, Bauer KS, Bostick-Bruton F, Kulpa V, Fuse E, Tompkins A, Noone M, Goldspiel B, Pluda J, Figg WD, Liotta LA. A phase I trial of carboxyamido-triazole and paclitaxel for relapsed solid tumors: Potential efficacy of the combination and demonstration of pharmacokinetic interaction. Clin Cancer Res 2001;7:1600-1609.
387. Berlin J, Tutsch KD, Hutson P, Cleary J, Rago RP, Arzoomanian RZ, Alberti D, Feierabend C, Wildin G. Phase I clinical and pharmacokinetic study of oral carboxyamidotriazol, a signal transduction inhibitor. J Clin Oncol 1997;15:781-789.
388. Bauer KS, Figg WD, Hamilton JM, Jones EC, Premkumar A, Steinberg SM, Dyer V, Linehan WM, Pluda JM, Reed E. A pharmacokinetically guided phase II study of carboxyamido-triazole in androgen-independent prostate cancer. Clin Cancer Res 1999;5:2324-2329.
389. Nakashima T, Hirano S, Agata N, Kumagai H, Isshiki K, Yoshioka T, Ishizuka M, Maeda K, Takeuchi T. Inhibition of angiogenesis by a new isocoumarin, NM-3. J Antibiot (Tokyo) 1999;52:426-428.
390. Yin L, Ohno T, Weichselbaum R, Kharbanda S, Kufe D. The novel isocoumarin 2-(8-hydroxy-6-methoxy-1-oxo-1H-2-benzopyran-3-yl) propionic acid (NM-3) induces lethality of human carcinoma cells by generation of reactive oxygen species. Mol Cancer Ther 2001;1:43-48.
391. Reimer CL, Agata N, Tammam JG, Bamberg M, Dickerson WM, Kamphaus GD, Rook SL, Milhollen M, Fram R, Kalluri R, Kufe D, Kharbanda S. Antineoplastic effects of chemotherapeutic agents are potentiated by NM-3, an inhibitor of angiogenesis. Cancer Res 2002;62:789-795.
392. Salloum RM, Jaskowiak NT, Mauceri HJ, Seetharam S, Beckett MA, Koons AM, Hari DM, Gupta VK, Reimer C, Kalluri R, Posner MC, Hellman S, Kufe DW, Weichselbaum RR. NM-3, an isocoumarin, increases the antitumor effects of radiotherapy without toxicity. Cancer Res 2000;60:6958-6963.
393. Kozin SV, Boucher Y, Hicklin DJ, Bohlen P, Jain RK, Suit HD. Vascular endothelial growth factor receptor-2-blocking antibody potentiates radiation-induced long-term control of human tumor xenografts. Cancer Res 2001;61:39-44.
394. Sakamoto T, Ishibashi T, Kimura H, Yoshikawa H, Spee C, Harris MS, Hinten DR, Ryan SJ. Effect of tecogalan sodium on angiogenesis in vitro by choroidal endothelial cells. Invest Ophthalmol Vis Sci 1995;36:1076-1083.
395. Tanaka NG, Sakamoto N, Inoue K, Korenaga H, Kadoya S, Ogawa H, Osada Y. Antitumor effects of an antiangiogenic polysaccharide from an Arthrobacter species with or without a steroid. Cancer Res 1989;49:6727-6730.
396. Yunmbam MK, Wellstein A. The bacterial polysaccharide tecogalan blocks growth of breast cancer cells in vivo. Oncol Rep 2001;8:161-164.
397. Yoshikawa H, Ishibashi T, Hata Y, Inomata H, Sueishi K. The suppressive effect of tecogalan sodium on in vitro angiogenesis via the periendothelial proteolytic activities. Ophthalmic Res 2000;32:261-269.
398. Eckhardt SG, Burris HA, Eckardt JR, Weiss G, Rodriguez G, Rothenberg M, Rinaldi D, Barrington R, Kuhn JG, Masuo K, Sudo K, Atsumi R, Oguma T, Higashi L, Fields S, Smetzer L, Von Hoff DD. A phase I clinical and pharmacokinetic study of the angiogenesis inhibitor, tecogalan sodium. Ann Oncol 1996;7:49l-496.
399. Miller KD, Sweeney CJ, Sledge GW Jr. Redefining the target: Chemotherapeutics as antiangiogenics. J Clin Oncol 2001;19:1195-206.
400. Belani C, Lynch T. Docetaxel (Taxotere) in combination with platinums in patients with non-small cell lung cancer: Trial data and implications for clinical management. Semin Oncol 2001;28:10-14.
401. Burris HA III. Docetaxel (Taxotere) plus trastuzumab (Herceptin) in breast cancer. Semin Oncol 2001;28:38-44.
402. Calderoni A, Cerny T. Taxanes in lung cancer: A review with focus on the [European experience. Crit Rev Oncol Hematol 2001;38:105-127.
403. Choy H. Taxanes in combined modality therapy for solid tumors. Crit Rev Oncol Hematol 2001;37:237-247.
404. Hortobagyi GN. Recent progress in the clinical development of docetaxel (Taxotere). Semin Oncol 1999;26:32-36.
405. Rose WC, Fairchild C, Lee FY. Preclinical untitumor activity of two novel taxanes. Cancer Chemother Pharmacol 2001;47:97-105.
406. Milas L, Milas MM, Mason KA. Combination of taxanes with radiation: Preclinical studies. Semin Radiat Oncol 1999;9:12-26.
407. Hennequin C, Favaudon V. Biological basis for chemo-radiotherapy interactions. Eur J Cancer 2002;38:223-230.
408. Herscher LL, Cook J. Taxanes as radiosensitizers for head and neck cancer. Curr Opin Oncol 1999;11:183-186.
409. Mason KA, Kishi K, Hunter N, Buchmiller L, Akimoto T, Komaki R, Milas L. Effect of docetaxel on the therapeutic ratio of fractionated radiotherapy in vivo. Clin Cancer Res 1999;5:4191-4198.
410. Grant DS, Williams TL, Zahaczewsky M, Dicker AP. Comparison of antiangiogenic activities using paclitaxel (taxol) and docetaxel (taxotere). Int J Cancer 2003;104:121-129.
411. Kerbel RS. Tumor angiogenesis: Past, present and near future. Carcinogenesis 2000;21:505-515.
412. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995;1:27-31.
413. Fox SB, Gasparini G, Harris AL. Angiogenesis: pathological, prognostic, and growth-factor pathways and their link to trial design and anticancer drugs. Lancet Oncol 2001;2:278-289.
414. McCarty MF, Liu W, Fan F, Parikh A, Reimuth N, Stoelzing O, Ellis LM. Promises and pitfalls of anti-angiogenic therapy in clinical trials. Trends Mol Med 2003;9:5358.
415. Cristofanilli M, Charnsangavej C, Hortobagyi GN. Angiogenesis modulation in cancer research: Novel clinical approaches. Nat Rev Drug Discov 2002;1:415-426.
416. Davis DW, McConjey DJ, Abbruzzese JL, Herbst RS. Surrogate markers in antiangiogenesis clinical trials. Br J Cancer 2003;89:8-14.
417. Blagosklonny MV. Antiangiogenic therapy and tumor progression. Cancer Cell 2004;5:13-17.
418. Inai T, Mancuso M, Hashizume H, Baffert F, Haskell A, Baluk P, Hu-Lowe DD, Shalinsky DR, Thurston G, Yancopoulos GD, McDonald DM. Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. Am J Pathol 2004;165:35-52.
419. Vosseler S, Mirancea N, Bohlen P, Mueller MM, Fusenig NE. Angiogenesis inhibition by vascular endothelial growth factor receptor-2 blockade reduces stromal matrix metalloproteinase expression, normalizes stromal tissue, and reverts epithelial tumor phenotype in surface heterotransplants. Cancer Res 2005;65:1294-1305.
420. Tong RT, Boucher Y, Kozin SV, Winkler F, Hicklin DJ, Jain RK. Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res 2004;64:3731-3736.
421. Jain RK. Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy. Science 2005;307:58-62.
422. Winkler F, Kozin SV, Tong RT, Chae SS, Booth MF, Garkavtsev I, Xu L, Hicklin DJ, Fukumura D, di Tomaso E, Munn LL, Jain RK. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: Role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell 2004;6:553-563.
423. Thorpe PE, Chaplin DJ, Blajey DC. The First International Conference on Vascular Targeting: Meeting overview. Cancer Res 2003;63:1144-1147.
424. Tosetti F, Ferrari N, De Flora S, Albini A. Angioprevention: Angiogenesis is a common and key target for cancer chemopreventive agents. FASEB J 2002;16:2-14.